Genetic Aberrationsin Myeloma Cells by Våtsveen, Thea Kristin
Genetic Aberrations
in Myeloma Cells
Thesis for the degree of Philosophiae Doctor
Trondheim, May 2009
Norwegian University of Science and Technology
Faculty of Medicine
Department of Cancer Research and Molecular Medicine
Thea Kristin Våtsveen
NTNU
Norwegian University of Science and Technology
Thesis for the degree of Philosophiae Doctor
Faculty of Medicine
Department of Cancer Research and Molecular Medicine
© Thea Kristin Våtsveen
ISBN 978-82-471-1543-5 (printed ver.)
ISBN 978-82-471-1544-2 (electronic ver.)
ISSN 1503-8181 
Doctoral theses at NTNU, 2009:83
Printed by NTNU-trykk
 1
Genetiske avvik i myelomceller 
 
Myelomatose (beinmargskreft) er kreft i plasmacellene i beinmargen. Det er 
den nest vanligste hematologiske kreftformen og rammer ca 300 personer i 
Norge hvert år. Kun 15% av pasientene er under 65 år. Det finnes ingen 
helbredende behandling for denne sykdommen, men i de siste årene har 
behandlingen blitt forbedret og i snitt lever pasientene nå i 5 år etter 
diagnosetidspunktet. 
 
Genetikken i myelomatosecellene er ikke godt kartlagt, men grovt kan 
sykdommen deles inn i to genetiske grupper basert på antall kromosom og 
tilstedeværelse av translokasjoner i genet for den tunge immunglobulingenet 
(IGH). Den ene typen, hyperdiploid myelomatose, har 48-74 kromosom og 
sjelden IGH-translokasjoner, mens den andre hovedtypen, ikke-hyperdiploide 
myelomatose, har under 48 eller over 74 kromosom og ofte IGH-
translokasjoner. Den hyperdiploide gruppen kjennetegnes ved at det ofte er 
tre kopier av minst fire av de åtte kromosomene 3, 5, 7, 9, 11, 15, 17, 19 og 
21, men man vet enda ikke hva den grunnleggende genskaden som fører til 
kreftutviklingen er. Hos den ikke-hyperdiploide gruppen er det et fellestrekk at 
gen som er involvert i IGH-translokasjonen er den type gen som kan bidra i 
kreftutvikling. 
  
Når man studerer myelomatose i laboratoriet bruker man vanligvis cellelinjer 
som er udødeliggjorte celler fra myelomatosepasienter. Alle til nå publiserte 
cellelinjer er ikke-hyperdiploide, og derfor har mesteparten av 
laboratorieforskningen på myelomatose blitt gjort på celler som bare 
representerer halvparten av pasientene.  
 
I denne doktorgraden er det fokusert på genetikken til myelomatoseceller. Det 
er både lagt vekt på å beskrive cellelinjene i bruk på laboratoriet og å 
undersøke både generelle og spesifikke avvik i celler fra 
myelomatosepasienter.  
 
Første artikkel er en beskrivelse av cellelinjen OH-2 som ble etablert i 
Trondheim i 1992. Det viktigste funnet er at cellelinjen OH-2 er den første 
hyperdiploide cellelinjen som er beskrevet. Cellelinjen har tre kopier av 
kromosom 3, 7, 15 og 21 og den har ingen IGH-translokasjon. Den har 
derimot en del av IGK (Immunglobulin lettkjede kappa-genet) satt inn mellom 
genene MAFB og MYC i en kompleks translokasjon.  
Andre artikkel er en undersøkelse av Fibroblast vekstfaktor 3 (FGFR3). 
Cellelinjen INA-6 har ikke den vanlige translokasjonen mellom IGH og 
FGFR3, som er den eneste beskrevne årsaken til uttrykk av FGFR3 i 
myelomceller, men den uttrykker likevel FGFR3. INA-6 har i stedet en ekstra 
kopi av FGFR3, noe vi tror er skyld i uttrykket av FGFR3 i denne cellelinjen. Vi 
viser at uttrykket av FGFR3 er viktig i denne cellelinjen.  
Tredje artikkel beskriver fosfatase i regenerativ lever 3 (PRL3), som tidligere 
er vist å være overuttrykt i metastaser i andre kreftformer. Det er også vist at 
ekstra kopier av PRL3 genet er funnet i noen av disse metastasene. Vi 
undersøkte derfor om dette også var tilfellet i myelomatose. Det ser ikke ut til 
at ekstra kopier er utbredt i myelomatose, og det er mer sannsynlig at andre 
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faktorer enn ekstra genkopier er årsaken til høyt nivå i myelomcellene 
undersøkt. 
Fjerde artikkel beskriver BCL3 som uttykkes i myelomceller som en respons 
på stimulering av forskjellige vekstfaktorer. BCL3 genet er involvert i 
translokasjoner i andre kreftformer og vi fant også en translokasjon i BCL3 
locus i en pasient. Både PRL3 og BCL3 er høyt uttrykt i en undergruppe av 
pasienter med dårlig prognose, og begge genene/proteinene kan være viktige 
hos disse pasientene.  
Femte artikkel er en foreløpig analyse av genetisk avvik og kliniske parametre 
som blant annet Beta-2-mikroglobulin og beinlesjoner hos nydiagnostiserte 
myelomatosepasienter i Norge. Vi fant ingen spesielle korrelasjoner mellom 
de ulike parameterne ved diagnose. 
 
Arbeidet er utført i perioden 2006-2008 ved NTNU og St.Olavs hospital, med 
støtte fra Norges forskningsråd (NFR).  
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1. GENERAL INTRODUCTION 
 
1.1 Multiple myeloma 
 
1.1.1 Multiple myeloma epidemiology 
 
Multiple Myeloma (MM) has probably existed for ages. Morse et al. described 
possible MM in skeletons from Indians (AD200-1300)1. The first published 
case of MM in the literature is Sarah Newburry, who was described by Samuel 
Solly in 18442. Not until 1873 the term ‘multiple myeloma’ was introduced by 
the Russian von Rustizky3. The name came from the many tumors (greek, 
myelos=marrow, oma= tumor) that were present in the patient’s bones. 
 
24 500 persons in Norway are diagnosed with cancer each year. MM is the 
second most common haematological malignancy and 305 new cases were 
reported to the Cancer Registry in 2006. It is primarily a disease of the elderly 
and only 15 % of the patients are below the age of 65. MM is more common in 
men, with male:female ratio 1.5:14. It is still an incurable disease but in the 
recent years with new therapy median survival is 5 years5. Also, some 
patients can live >10 years after diagnosis6,7. A Swedish study from 1973-
2003 found that 1-year survival has increased and that survival after 5- and 10 
years also have increased, but only in patients of age below 708. In 2004 MM 
was responsible for 2.5% of all cancer-related deaths in Norway4.  
 
1.1.2 Clinical characterization 
 
MM is a neoplasm of long-lived bone marrow plasma cells (PC)9. This 
accumulation of malignant plasma cells leads to monoclonal production of 
immunoglobulins (Ig). This can be measured in patient serum or urine, and 
excess secretion can lead to renal failure. The PCs will usually not be evenly 
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distributed in the bone marrow (BM), but be located in high numbers 
especially in the red bone marrow. In these locations the typical bone lesions 
arises, and bone pain is a common and debilitating symptom of MM. The 
international staging system (ISS) is the standard for staging of MM10.  
 
1.1.3 Prognostic factors 
 
Several prognostic factors that identify groups of MM patients have been 
found. Not including genetic variations, which will be discussed later, 
predictors of survival are; age, ISS, hemoglobin level, creatinine, calsium, 
albumin, immunoglobulin subtype, and bone marrow infiltration11.   
 
1.1.4 The pathogenesis of multiple myeloma 
 
MM, usually precedes by the pre-malignant tumor monoclonal gammopathy of 
undetermined significance (MGUS)12. MGUS is the most common lymphoid 
tumor and occurs in approximately 3% of persons over the age of 5013. MGUS 
is asymptomatic, and the line of a progression to MM increases by 1% each 
year14. Even though the prevalence of MGUS and MM is higher in African-
Americans15, and some evidence of familial clustering is seen16-18, the effects 
of the genetics and the environment are not clear. An intermediate, usually 
asymptomatic, but more adverse pre-malignant stage is referred to as 
smoldering multiple myeloma (SMM). SMM progresses to MM at a rate of 
approximately 10-20% per year. It is however thought that not all MM cases 
progress through SMM19 (also shown in figure 3).  
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1.2 Genetics in MM 
 
Cancer is a genetic disease at the cellular level. The genetic disease can 
generally be divided into two scenarios of genetic events which contribute to 
transformation of the cell: Inactivation of genes by deletions, mutations, 
epigenetics, microRNAs or activation of genes by amplifications, 
translocations, mutations, epigenetics and microRNAs. The genes involved 
can be divided into three groups: oncogenes, tumor suppressor genes and 
DNA repair genes. Proto-oncogenes are genes that in healthy cells are 
involved in normal growth. Aberrations in proto-oncogenes lead to oncogenes 
that result in production of proteins that will enhance the cells’ ability to growth 
and enhance cell divisions. Tumor suppressor genes are normal genes that 
codes for proteins that slow down cell growth and cell division or induce 
apoptosis. These genes might lead to malignancies if they are inactivated. 
DNA repair genes codes for proteins that remove mutations that arise during 
cell division. If these genes get mutated and loose their function, mutations in 
proto-oncogenes and tumor suppressor genes will not be repaired.  
 
1.2.1 Genetic aberrations lead to dysregulation of several genes  
 
To get a functional antibody repertoire it is crucial for the B-cell lineage to be 
able to rearrange its germ-line DNA. This is essential to create a functional 
adaptive immune system to fight infections. Hence, this is also a dual-edged 
sword and will occasionally lead to translocations of oncogenes to the Ig-loci. 
In all malignancies genetic aberrations are crucial for the development and 
transformation. In some malignancies there can be one or a few aberrations 
causing the transformation. In MM the initiating aberrations that lead to 
transformation are however still a mystery. It is unknown if there is any 
common genetic aberration in all MM patients. However, some aberrations 
are known and are shown to have impact on prognosis20.  
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Classical cytogenetics has historically been used to define genomic 
aberrations by analyzing hundreds of patients. It has however been difficult to 
generate metaphases of patient tumor cells in MM because of the primary 
cells’ slow proliferation rate. But recent studies using array comparative 
genomic hybridization (CGH) have revealed that virtually all MM patients have 
chromosomal abnormalities21,22.  
 
1.2.2 B-cell development 
 
Normal B-cell development is illustrated in figure 1. During adaptive immune 
response, normal B-cells initiate variation (diversity) and joining (V(D)J) 
recombination. During primary immune response the immature B-cells migrate 
to secondary lymphoid organs to form pre-germinal center PCs. B-cells that 
enter the germinal center undergo affinity maturations by multiple rounds of 
somatic hypermutation of immunoglobulin heavy chain (IGH)- and 
immunoglobulin light chains κ/λ (IGK/IGL)- V region sequences. Cells that 
express high-affinity antigen receptors are selected for survival and undergo 
Ig switch recombination. A subset of activated B-cells then mature into 
memory B-cell differentiation into memory B-cells that can reside in the body 
for decades and then be activated upon exposure to the same antigen. Other 
B-cells form post-germinal center plasma cells that home to the bone marrow 
where they can be as differentiated, non-proliferating, long-lived PC for 
months and even years23. 
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Figure 1 
Normal B-cell development. Figure with permission23 
 
1.2.3 Malignant B cell development: Translocations in MM involve three 
DNA modification systems 
 
The translocations in the Ig genes are common in many B cell tumors, as well 
as in MM, and are thought to be caused by either: I) V(D)J recombination 
early in the B-cell development, II) somatic hypermutation in germinal center B 
cells or III) switch recombination in germinal center B-cells (figure 1). These 
processes can cause double strand DNA breaks in or near Ig, and it is thought 
that the same mechanism can occur near oncogenes, with the consequence 
of Ig translocations24.  
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1.2.4 Primary translocations in MM 
 
Primary translocations in MM are reciprocal translocations between the IGH 
gene at 14q32 and seven known genes. These translocations are termed 
primary since they are seen in MGUS, i.e. occur early and might initiate 
transformation. In primary translocations one of the strong IGH enhancers 
(Eµ, Eα1 and Eα2) is juxtaposed to an oncogene/proto-oncogene. The switch 
translocations in MM separate the strong 3`α- and µ-enhancers of the IGH 
onto different derivative (der) chromosomes. The enhancers can thereby turn 
on or up the transcription of the juxtaposed gene. The reciprocal partners to 
IGH are: 4p16, MMSET/FGFR3; 11q13, Cyclin D1; 12p13, cyclin D2; 6p21, 
Cyclin D3; 16q23, MAF; 20q12, MAFB and 8q24.3, MAFA. Translocations 
involving an IGH locus are present in nearly 50% of pre-malignant MGUS 
tumors, approximately 60% of fully malignant MM tumors, and nearly 90% of 
human myeloma cell lines (HMCLs)25-28. Figure 2 gives an overview of a 
normal switch recombination and an illegimate switch recombination resulting 
in a t(4;14)23. 
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Figure 2 
This figure illustrates a reciprocal translocation between IGH on chromosome 
14 and FGFR3/MMSET on chromosome 4. The second line from the top shows 
germ line IGH gene, and the arrow up to the first line illustrates a normal switch 
recombination where the cells go from making IgM to IgG. The breakpoint 
leading to the translocation illustrated here is in the middle of the switch 
region and hereby dissociates the intronic enhancer (Eµ) and the 3'Eα. The 
double strand break dissociates the enhancers and the two ends are joined by 
another double strand breaks in another chromosome (here chr 4). By this the 
Eµ will be located on der(4) juxtaposed to MMSET, and can result in a hybrid 
mRNA transcript usually initiated from the Jh and the Iµ (intronic promoter). 
Also, the cryptic promoter (P*) on 4p16 can initiate transcription. The 3'Eα on 
der(14) dysregulates the expression of FGFR3. Illustration with permission23. 
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t(4;14) 
The t(4;14)(p16.3;q32) is one of the most common translocations and is 
present in 15% of newly diagnosed patients, but at a bit lower frequency in 
MGUS. The t(4;14) has not been described in other malignancies29. This 
translocation was also the first to show that IGH could dysregulate two genes 
at two derivative chromosomes, namely fibroblast growth factor receptor 3 
(FGFR3) and multiple myeloma SET domain (MMSET)30.  
 
The translocations result in ectopic expression of functional FGFR3 in 70 % of 
the t(4;14) patients31,32. The reason for the lack of FGFR3 expression in the 
last 30% is mainly loss of der(14)32. FGFR3 is one of 4 high-affinity tyrosine 
kinase receptors for the FGF family of ligands. It is normally expressed in the 
lungs and kidneys, and it is expressed at high levels in the developing central 
nervous system, precursor bone cartilage rudiments, and resting cartilage at 
the end of growing bones33. FGFR3 is not normally expressed in PCs34. 
However, the chimeric IGH/MMSET gene fusion product is expressed in all 
t(4;14) patients32,35. The MMSET isoform RE-IIBP has been shown to be a 
histone methyltransferase with transcriptional repression activity36. MMSET 
has also been shown to be of importance in cellular adhesion, clonogenic 
growth and tumorigenicity37, and knocking MMSET down has recently been 
shown to decrease the expression of genes that eventually decrease cell 
viability, adhesion and cell cycle progression38. 
  
t(4;14) has been associated with poor prognosis irrespective of FGFR3 
expression31. Genetic studies show also that ~85% of t(4;14) patients have a 
deletion (del)13 (described later). These two abnormalities together show a 
worse prognosis than t(4;14) alone29. However, not all patients with t(4;14) 
have the same poor prognosis, and it might be correlated with other factors. 
This was found by the newest large study by Intergroup Francophone du 
Myelome (IFM), where t(4;14) patients with low β2-microglobulin level showed 
longer survival compared to t(4;14) patients with high β2-microglobulin level20.  
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Figure 3 
IH-1, a HMCL established here in Trondheim39, has a t(4;14) (paper 2) and a 
fusion transcript detected by PCR with primers in Jh in IGH and exon 6 in 
MMSET. Left shows the gel with the specific fusion band next to the arrow. The 
joining area of IGH is fusioned to exon 4 of MMSET detected by sequencing the 
PCR product. The breakpoint in chromosome 4 is in the intron between exon 3 
and 4 in this particular HMCL. Illustration prepared by author.  
 
t(11;14) 
The t(11;14)(q13;q32) is also one of the most common translocations in MM 
patients and is present in ~15% of newly diagnosed patients as well as in 
MGUS. Cyclin D1 (CCND1) at 11q13 encodes CCND1 which is over-
expressed as a consequence of this translocation40. Myeloma over-expressed 
gene (MYEOV) is also in the same locus and has been shown to be over-
expressed. The function of this gene is not well known41. So far the oncogenic 
role of the cyclin D1 over-expression is not known either, even though the 
cyclin Ds control entry of the cell cycle to the S (DNA-synthesis) phase by 
binding and activating cyclin-dependent kinases -4 and -6, which 
phosphorylate the retinoblastoma proteins, and thereby promotes the cell 
cycle 42. Even though the cyclin Ds are involved in the cell cycle, the t(11;14) 
MMs are characterized by a low proliferation index43. Although an increased 
cyclin D1 expression does not cause increased proliferation, it might make the 
cells more susceptible to other proliferative stimuli from the microenvironment, 
e.g. BM stromal cells that express interleukin (IL)-6, insulin-like growth factor 
(IGF)-1 or other cytokines25. Early studies reported the t(11;14) patients to 
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show better survival44. However, later and larger studies did not confirm this 
better survival20,45.  
t(14;16), t(14;20) and t(8;14) 
The t(14;16)(q32;q23) is present in ~5% of MM patients46. This translocation 
is not known in other malignancies than MM29. The t(14;20)(q32;q11) is even 
less common and is present in less than 1% of MM patients47. The 
translocations dysregulate musculoaponeurotic fibrosarcoma oncogene 
homolog (MAF/c-MAF) and MAFB, respectively. MAF proteins belong to the 
activator protein (AP)-1 superfamily of basic leucine zippers. MAFs work as 
transcription factors that positively regulate e.g. cyclin D2 (CCND2), Integrin 
β7 (ITGB7) and ARK5 together with other MAF-related genes26,48,49, that 
induce deregulation of cell cycle, cell-cell interaction and migration, 
respectively. Another feature is that MAF in oncogenesis has an ability to 
enhance the interaction between tumor cells and stromal cells49. Surprisingly, 
when compared to the translocation frequency, MAF was overexpressed in 
half of MM primary samples49. The mechanism behind this is not yet 
understood50, and with GEP only 8-10% of the samples with overexpression 
of MAFs cluster together51. MAFA (L-MAF) on 8q24.3 has also been shown to 
be involved in MM, but at a much lower level (<1%) (mentioned in figure 5)9. 
The t(14;16) has been associated with short survival28. 
 
t(6;14) and t(12;14)  
The t(6;14)(p21;q32) and t(12;14)(p13;q32) dysregulate cyclin D3 (CCND3) 
and CCND2 and are present in ~2% and <1% of MM respectively9. The 
molecular consequences of these translocations are not well characterized.  
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1.2.5 Structures of IGH translocations in MM 
 
The structures of IGH translocations in MM tumors can be divided into four 
groups; a) the classical balanced translocations have no loss of DNA, and can 
be distinguished by Fluorescence in situ Hybridization (FISH) (described later) 
by dissociation of the IGH-constant region (CH) and IGH-variable region (VH) 
signals. CH is left on der(14) while VH is located on the telomere of the other 
derivative chromosome. This is the typical pattern found in the five primary 
IGH translocations; b) the variant translocations are distinguished by the 
whole IGH locus translocated to a derivative chromosome. Seen by FISH the 
CH and VH is colocalized on the derivative chromosome, and the der(14) has 
no CH/VH signal. It is therefore not possible to detect this variant translocation 
by  conventional interphase FISH; c) the unbalanced translocations are 
described by a FISH pattern where there is either a der(14) CH signal or a VH 
signal, and the other derivative chromosome is lost; d) The fourth group of 
IGH translocations is the simple insertions. The CH signal is dissociated from 
the VH signal and is found internally on the recipients chromosomes. Usually, 
no whole chromosome paint (WCP)14 is detected together with the CH 
signal23,52. Figure 4 explains these kinds of translocations with metaphase 
FISH picture and chromosome illustration. By Spectral Karyotyping (SKY) it is 
only possible to detect some of the balanced translocations, and unbalanced 
translocations der(14). The other variants are hard to detect because of the 
relative small fragments of DNA that have been translocated. Hence, FISH 
with locus specific probes must be used. 
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Figure 4. The different IGH translocations in MM: A) The classical IGH 
translocation is demonstrated by the t(4;14) in HMCL IH-1 (paper II). The two 
chromosomes to the left are shown with CH in green and VH in red, with VH 
translocated to chromosome 4. The two chromosomes to the right show the 
specific translocation with IGH in green and FGFR3/MMSET in red. A fusion 
signal between the labeled loci appears yellow. WCP in Aqua on chromosome 
14. The chromosome drawing shows where the FISH probes cover the IGH 
gene. CH probe is labeled in green and VH probe is labeled in red. The der(14) 
and der(4) chromosome drawing depict the two derivative chromosomes and 
its translocation partner. The black small circles image the centromere. B) The 
variant IGH translocation is depicted by a figure because our laboratory does 
not have a HMCL with known variant IGH translocation. The der(14) to the left 
has lost the whole IGH which has been translocated to chromosome 8. This 
translocation results in a t(8;14) that dysregulates MYC, and can be found in 
e.g. HMCL XG-152. The chromosome drawing to the right depicts the der(8). C) 
The unbalanced translocation is depicted by INA-6 where der(11) is lost, and 
der(14) with CH in green is translocated to chromosome 11 with CCND1 in red. 
WCP aqua on chromosome 14. Chromosome drawing to the right depicts the 
only derivative translocated chromosome. D) CH in green has dissociated from 
VH and is inserted into CCND1 in red on der(11) in U266. The chromosome 
drawing to the right depicts that a small part of CH is juxtaposed to CCND1. 
The black box depicts the rest of chromosome 11. The figure is made by the 
author after inspiration in article text from ref23,52. 
 
1.2.6 Secondary translocations 
 
Secondary translocations occur during late stage of MM progression and do 
not involve B-cell specific DNA modification mechanisms. Secondary 
translocations also include the IGL gene (10%) and IGK (<1%). The 
secondary translocations are rarely reciprocal, and can also be complicated 
insertions of the genes53. Almost 20% of MM patients with IGH translocation 
involved a non-recurrent translocation partner, and many of these are 
secondary translocations29,52. 
 
MYC 
 
Perhaps the most important secondary translocated gene in MM is MYC at 
8q24. MYC was one of the first oncogenes identified, and has been linked to a 
spectrum of malignancies54. MYC is an important transcription factor that 
regulates cell growth, differentiation and apoptosis. In Burkitts lymphoma, 
MYC translocation to an Ig-gene is an early and unifying event55. This is in 
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contrast to MM where dysregulation of MYC apparently is caused by complex 
genomic rearrangements during late stages of MM progression involving B-
cell specific DNA modification mechanisms56. In MM, IGH-MYC translocations 
are often a part of a complex rearrangement. Almost 90% of the HMCLs have 
MYC rearrangements and express high amounts of MYC detected on 
microarray (e.g. Paper I). Many MYC rearrangements involve an Ig locus, but 
the break point is only near the locus and not within the switch regions or the 
V(D)J sequence. This is similar to other IGH secondary translocations where 
the brake points are not involving J or switch region. The MYC translocations 
are mostly non-reciprocal or involve insertions, amplifications, inversions, and 
three chromosomes are often involved in the rearrangement57. In e.g. HMCL 
JJN-3 the IGH-MYC fusion was found on two different chromosomes 58. And 
the HMCL RPMI-8226 has the MYC-region associated with IGL in a complex 
translocation to c-MAF56. This is very much like the IGK rearrangement in OH-
2, where the IGK3’-enhancer is juxtaposed to MYC and MAFB (paper I). It 
was quite difficult to detect this IGK3’-enhancer by FISH, and similar 
translocations in other HMCLs and patients can easily be missed. MYC 
rearrangement has the same prevalence in both hyperdiploid and non-
hyperdiploid tumors (explained later)52. MYC rearrangements are however 
rare in MGUS and SMM and are present in ~15 % of newly diagnosed MM 
tumors59. 40 % of the MYC translocations do not involve an Ig locus57. MYC 
translocation has no apparent impact on the progression of the disease20, but 
it might have a yet hidden prognostic impact, since MYC is expressed also by 
other, yet unknown, mechanisms than translocations in the patients20,60.  
 
MYC has many target genes, and it is not known which are the most important 
in MM. Lately interferon regulatory factor 4 (IRF4, also known as multiple 
myeloma oncogene 1 (MUM1)) and MYC were found to positively reinforce 
the expression of each other in MM HMCL. IRF4 worked as a transcription 
factor that targeted MYC in myeloma cells, and at the same time IRF4 was 
also a downstream target gene for MYC. Knocking out IRF4 was found to kill 
MM HMCLs, as did the knocking out of MYC61. 
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1.2.7 Other genetic aberrations 
Chromosome 13 deletion 
 
Chromosome 13 deletion (del13), or more specifically 13q14 retinoblastoma 
(RB)-1 deletion occurs in about half of MM karyotypes62. This abnormality is 
probably an early or primary event, since it is observed with similar frequency 
in MGUS and in patients with relapsed MM. The molecular consequences are 
not well known, and because most del13s are monosomies, many genes are 
lost and may be deregulated. GEP has revealed that this feature has a 
molecular signature60,63. Del13 was one of the first genetic markers to be used 
as a prognostic marker64-66. University of Arkansas for Medical Science 
(UAMS) published in 1995 the first findings of monosomy 13 having negative 
impact on survival67, which was also confirmed later in their total therapy II 
study68. Chiecchio claims there is prognostic impact in del13 when found by 
conventional cytogenetics but not by interphase FISH only69. In the recent IFM 
study, del13 identified with FISH was not an independent prognostic factor, 
but was associated with poor prognosis related to the concomitant t(4;14) or 
del17p. Del13 may therefore not be a specific prognostic factor after all in MM, 
and may be considered a pseudomarker or a marker frequently associated 
with other more specific poor prognostic factors20.  
 
Deletion of 17p13 
 
In MM it has more recently been found a deletion in chromosome 17p in 10% 
of newly diagnosed patients. TP53 is located on 17p13 and down-regulation 
of the gene was correlated to the 17p13 deletion, which therefore makes 
TP53 the top-target gene to be the important gene in the deleted locus. 
Mutation in TP53 is associated with significantly shorter survival, with median 
survival only 1.5 years70, and an IFM study found it associated with poor 
outcome20. Since TP53 is involved in apoptosis and induced by most 
chemotherapeutic agents, the loss or/and mutations in TP53 may participate 
in the treatment resistance seen in del17 patients29. It appears that mutations 
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in TP53 are rare, and it was reported in only 3% of the patients in a large 
study. Half of the cases with mutation were correlated to hemizygous loss of 
17p1370.  
 
Chromosome 1 
 
As we also show in paper I, for the OH-2 HMCL and primary cells, the 1q 
region is gained. This is also the case in about one third of MM patients71. 
UAMS reports poor outcome of patients with 1q abnormalities, with locus 
1q21 especially in focus72, but a Mayo study and IFM report that the 
prognostic value disappears when combined with other classical biological 
and genetic prognostic factors20,29,73. Since the correlation between the 1q 
amplification and prognosis is weak it is suggested that this is more of a 
marker of a clonally advanced and genomic unstable tumor that is more likely 
to have a faster progression9. 
 
Deletions in 1p are also common. A study on 1p32 shows that 15% of MM 
patients have a deletion of this locus harboring CDKN2C. Patients with hemi- 
or homozygote deletions had a shorter overall survival and the homozygote 
deleted cases were the most proliferative myelomas74. 
 
1.2.8 Ploidity 
 
MM can be genetically classified in two: hyperdiploid (HRD) and non-
hyperdiploid (NHRD) tumors. It has been established that both MM and 
MGUS can be separated by these two groups distinguishable by chromosome 
content75-78. Approximately 50% of tumors are hyperdiploid and contain 48-74 
chromosomes. Although this classification appears somehow artificial, the 
HRD appears as a relatively uniform group, typically with non-random gains of 
at least four of eight odd-numbered chromosomes (3, 5, 7, 9, 11, 15, 19, 21). 
The remaining tumors are non-hyperdiploid, containing less than 48 and/or 
more than 74 chromosomes (near tetraploid). These two groups are further 
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classified by IGH translocations with the seven reciprocal partners described 
above. These are present in about 70% of NHRD tumors but only in about 
15% of HRD tumors79.  
 
It appears that recurrent IGH translocations and HRD are primary events 
occuring early in pathogenesis. Secondary translocations, which include most 
IGH rearrangements not involving one of the seven recurrent partners, most 
IGL and IGK rearrangements, and MYC rearrangements, appear to contribute 
equally to progression of both HRD and NHRD tumor52. 
 
A lot has been published on NHRD MM with primary translocations, and 
virtually all HMCLs used in laboratories are derived from NHRD tumors. On 
HRD MM, however, there has just been a few publications, and only from 
more recent years. Two studies from Chng et al have exploited the GEP and 
the prognostic factors for the HRD tumors. They conclude that HRD patients 
have a better partial event-free survival and overall survival than NHRD 
patients. The presence of IGH translocations, especially those with unknown 
partners, has a negative impact on the HRD tumors. These translocations are 
perhaps a result of later secondary translocation events due to genomic 
instability in advanced tumors80. The GEP was able to identify four biologically 
relevant subtypes with prognostic implications. Cluster 1 is defined by 
overexpression of various cancer testis antigens and mitotic/proliferation-
related genes. Since hypomethylation is implicated in the expression of 
cancer testis antigens in tumors, it is a possibility that the GEP is a surrogate 
marker for deregulated epigenetic mechanism. Cluster 2 is defined by 
overexpression of hepatocyte growth factor (HGF) and interleukin (IL)-6 
genes. Deregulation of HGF induces migration, survival and growth via 
multiple downstream pathways. IL-6 mediates similar effects. Cluster 3 is 
defined by overexpression of genes involved in nuclear factor (NF)-κB-
signalling. NF-κB is important in many downstream effects of MM–bone 
marrow interactions. Cluster 4 was less defined, except for the lack of high 
expression of the above genes, and with particularly low expression of HGF81. 
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Another interesting finding is that HRD are more common in MGUS than 
NHRD. In addition, del13 is far more common in the HRD MGUS, in contrast 
to in MM where the del13 is more common with NHRD82.  
 
1.2.9 Molecular pathogenesis 
 
The latest model for the molecular pathogenesis by Chng et al is shown in 
figure 5. The figure summarizes most of the events described above. Figure 5 
shows the two pathways of pathogenesis; the NHRD and the HRD pathway. 
Four early events are described, for which the timing is yet unknown: IGH-
translocations, HRD with multiple trisomies, loss of chromosome 13 
sequences and dysregulation of a CCND gene. Later events include other Ig 
translocations, and secondary translocations involving MYC, mutations of 
KRAS, NRAS or FGFR3 in t(4;14) tumors. Inactivation of TP53 by various 
mechanisms is a progression event. Also, mutations to constitutively activate 
the nuclear factor (NF)-κB-pathway occur in half of MM tumors. This might 
induce independence from environmental factors necessary for activating 
pathways at earlier stages. Also, other secondary translocations, inversions, 
insertions, deletions, methylation of promotors or genes and additional 
inactivation of the RB1 pathway can occur at all stages9. 
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Figure 5 
Description of disease stages, with molecular pathogenesis and timing of 
oncogenic events in the tumorigenesis of MM. The degree of overlap between 
triangles estimates the percentage overlap of genetic subgroups harboring 
coexisting genetic abnormalities. The translocation partners in the IGH 
translocation (TLC) group are ordered according to increasing frequency of 
coexisting del13. The different mutations activating signal or cell-cycle 
pathways are mutually exclusive, i.e. RAS and FGFR3 always occur in different 
patients. *The 8q24 partner referred to here is MAFA; MYC is also located in 
this locus, but is usually a secondary IGH translocation. Illustration with 
permission 9  
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1.3 Genetic and molecular classification systems of MM 
 
Several MM research groups have made their own classification systems for 
MM. Since the survival period for patients varies from a few months to more 
than ten years it is important to be able to identify different risk groups. New 
advanced technologies have made it easier to look globally at genetic 
aberrations at both DNA and RNA levels. Perhaps some models are more 
useful for classifications of single patients than others. In the future, we 
hopefully have easily accessible technologies to do studies at the protein 
level, which might make it easier to see the full picture of the current 
classifications. I also miss a microRNA profile study in MM, but hopefully it will 
come in reasonable future. A classification system with high predictive power 
would hopefully contribute to tailored treatment for the MM patients. 
 
1.3.1 Translocation and cyclin D (TC) classification 
 
A characteristic feature of MM cells is the expression of CCNDs. Together 
with the occurrence of IGH translocations, CCND expression form the basis 
for the TC classification of MM. This classification of the patients is based on 
the observation that most tumor cells in MGUS and MM, have relatively high 
levels of CCND mRNAs. This, combined with the type of primary IGH 
translocation, gives the eight groups [listed a)-h)] described by Bergsagel and 
Kuehl (2005). The groups are: a) 11q13: with t(11;14) and CCND1 
expression, NHRD, (16 % of cases); b) 6p21: with t(6;14) and CCND3 
expression, NHRD, (3 %); c) D1: no t(11;14) but with CCND1 expression, 
HRD, (34 %); d) D1+D2: As D1 but with additional CCND2 expression, HRD, 
(6 %); e) D2: CCND2 expression, HRD=NHRD, (17 %); f) none: express no 
cyclins, NHRD, (1 %); g) 4p16: with t(4;14)  and CCND2 expression, 
NHRD>HRD, (15 %) and h) MAF: with either t(14;16) or t(14;20) and C-
MAF/MAFB and CCND2 expression, NHRD, (7 %)25. 
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This classification system has the advantage that it involves few markers that 
need to be measured, and the primary translocations can easily be detected 
with interphase FISH. However, the TC classification does not identify the 
HRD MM, and the majority of these patients will fall into the D1 and D1+D2 
groups. There is no significant difference in survival for D1 and D1+D29,25,26.  
 
1.3.2 Molecular classification based on gene expression profile 
 
At UAMS, seven groups of MM patients were identified based on co-
expression of unique gene clusters based on gene expression profile (GEP). 
The seven subgroups are classified by unique expression patterns. PR: 
proliferation; LB: low bone disease; MS: MMSET; HY: hyperdiploid; CD-1: 
cyclin D1; CD-2: cyclin D3; MF: MAF/MAFB. These groups also identify the 
primary IGH translocations51. This classification is relevant because it defines 
the high-risk groups, PR and MS. However, the study is made on a large set 
of genes and it might be difficult to use it clinically for single patients9. 
 
UAMS also identified a 17-gene model based on GEP, sufficient for defineing 
the high risk myeloma patient. Most of these genes are on chromosome 1 and 
the profile does not detect the different IGH translocation groups as in their 
gene cluster grouping72. Similar to this, the IFM proposes a 15-gene model to 
define the high risk myeloma patient. The two models do not share a single 
common gene. When applying both the 17- and the 15-gene model together, 
it is possible to identify subgroups that e.g. do not benefit from bortezomib83. 
Both these models might be very useful for tailored therapy. 
 
1.3.3 Genetic factors and β-2 microglobulin based classification 
 
The IFM has one of the newest models to predict prognosis. It uses genetic 
factors t(4;14) and 17p13 deletion detected by FISH combined with β-2 
microglobulin level. The high risk group is defined by the presence of either 
t(4;14) or 17p13 deletion and β-2 microglobulin above 4, and it could dissect 
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the survival of patients in each ISS stage. This study shows that it is possible 
to find high risk groups with FISH and simple parameters like β-2 
microglobulins20. This might be one of the most easy ways for classifying the 
patients, and manageable for most hospitals. However, this did not correlate 
with the Eastern Cooperative Oncology Group (ECOG) clinical trials. They 
saw no difference in survival comparing t(4;14) and del17 patients with β-2 
microglobulin level. The IFM and the ECOG patients have been treated 
differently, and this factor might also be included to get the right picture of this 
way of classifying high risk patients84.  
 
1.3.4 Array Comparative Genomic Hybridization (CGH) based 
classification 
 
The two main genetic groups, HRD and NHRD can be detected using array 
CGH to classify MM. The array study by Carrasco et al. also divided the HRD 
into two subgroups based on gain of 1q, del13 in the poor prognosis group 
and trisomy 11 in the better prognosis group. The NHRD could also be 
separated in two groups mainly by one of them having chromosome 1 
abnormalities but with no significant difference in survival21. The finding on 
array CGH does not give more information than FISH regarding prognosis.  
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1.4 How to discover chromosomal abnormalities 
 
In 1914 Theodor Boveri described in his book “Zur Frage der Entstellung 
maligner Tumoren“, an hypothesis that chromosomal abnormalities were the 
cellular change that lead to transformation. But at the first part of the 20th 
century it was difficult to prove his hypothesis. Not until Caspersson et al. 
introduced techniques to detect the chromosome bands, the cytogenetic 
analysis was revolutionized. Each and every chromosome could now be 
identified by its specific bands85. One of the famous chromosome aberrations 
is the Philadelphia chromosome, discovered by Nowell and Hungerford in 
196086. This t(9;22) was the first documented bona fide genetic signature of 
malignancy. The discovery that this was a t(9;22) and not a deletion of chr 22 
was made because of improved techniques for chromosome banding, the 
Giemsa-banding (G-banding)87. Still Giemsa-banding is routinely used to 
visualize chromosome bands. Unfortunately the genomic aberrations needs to 
be more than 3Mb to be detected88.  
 
In situ hybridizations allow analysis of nucleic acids in its cytogenetic context 
on the chromosome, in the nucleus or in tissues. This technique was 
developed in the late 60ies using radioactive labeled probes. In the 80ies the 
radioactivity was replaced by the less harmful fluorescence dyes. 
Fluorescence in situ hybridization (FISH) was born89. 
 
1.4.1 Fluorescence in situ hybridization 
 
FISH uses fluorescence labeled DNA probes that are homologous to the 
target gene or area. There are basically three different FISH-probes; locus 
specific probes (LSI) that cover one gene/locus, centromeric enumeration 
probes (CEP) and whole chromosome paint (WCP) probes. FISH on nuclei in 
interphase (interphase FISH), uses one to three LSI probes to e.g. discover 
chromosome translocations. CEP and LSI together are useful for detection of 
deletions or amplifications of genes and areas. The limitations here are that 
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you can only look at three to four colors at the same time, and it is necessary 
to have a hypothesis on what is wrong, in order to choose the right probes. In 
routine work, the detection of the primary IGH translocations and chromosome 
deletions in MM are done by interphase FISH on MM cells from patients. The 
IGH is labeled in e.g. green, and the other gene of interest, e.g. FGFR3, is 
labeled in red. A fusion signal, where green and red fluorescence are seen 
together, indicates that a translocation is present (Figure 6a). A rule of thumb 
is that in nuclei in interphase, a fusion signal between two probes means they 
are no more than 500kb apart.  
 
Metaphases and FISH on metaphase chromosomes give some more 
information about a tumors’ genetics. But because it is difficult to get 
informative metaphases from the low proliferative MM cells, this technique is 
therefore not suitable on a routine basis. However, FISH on metaphase 
chromosomes is a very useful technique for research purposes, especially 
when using HMCLs. The use of WCP, CEP and LSI probes together are often 
very informative for detecting new aberrations in the cell. Fig 6b shows HMCL 
OH-2 metaphase with both CEP and LSI probes. Doing the same experiment 
on interphase FISH would only give the number of MYC loci present 
compared to the number of chromosomes, and the fact that the extra copy 
was on the p-arm of chromosome 8 would have been missed.  
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Figure 6  
a) Interphase FISH on CD-138 separated MM cells from a patient. Arrows show 
fusion signals between IGH and FGFR3/MMSET. Green signals alone are 
normal IGH on chromosome 14, and red signals alone are normal 
FGFR3/MMSET on chromosome 4. 
b) Metaphase FISH on HMCL OH-2. CEP probes help determine the different 
chromosomes and identified an extra copy of MYC at chromosome 8 (paper I). 
Pictures prepared by author. 
 
1.4.2 Spectral Karyotyping (SKY) 
 
SKY is the deluxe variant of metaphase FISH. With SKY each chromosome 
gets its own pseudocolor based on the combination of fluorescence-labeled 
probes. The advantage is that it is easy to visualize and detect novel 
deletions, translocations and amplifications. The resolution however, is not 
great. To be able to detect an abnormality it needs to be larger than 3-5Mb. It 
is also not possible to know which part of the chromosome which is involved 
in the abnormality without consulting e.g. corresponding Giemsa-banding or 
doing LSI FISH. Successful multicolor/SKY FISH was first available in the 
90ies90,91. An example of SKY is given in section 4 in figure 7a of the HMCL 
RPMI 8226. 
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1.4.3 Array Comparative Genomic Hybridization 
 
Conventional comparative genomic hybridization (CGH) is a technique where 
DNA is extracted from e.g. a tumor sample, labeled in one color and normal 
DNA is labeled in another color, and both samples are co-hybridized to normal 
metaphase chromosomes. Amplifications or deletions in the tumor sample will 
then be visualized on the corresponding normal chromosome, and it is 
possible to detect the specific area with aberrations. This technique has been 
improved by replacing the metaphase chromosomes by a microarray chip 
where DNA from clones or sequences has been spotted on a slide. The 
samples are labeled the same way as in conventional CGH but are co-
hybridized to the array. The resolution is restricted only by the number of 
clones or spotted sequences. An array with overlapping clones will cover the 
whole genome92. An example of an array CGH of HMCL RPMI-8226 is shown 
in section 4 in figure 7b. This array CGH is made from bacterial artificial 
chromosomes (BAC) and Pi artificial chromosome (PAC) at a ~1 Mb 
resolution. In addition, it has a tiling path between 1q12 and the beginning of 
1q2593.  
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2. AIMS OF THE STUDY 
 
The overall objective of this work was to study the genetics of myeloma cells. 
Especially we wanted to focus on not well known genetic aberrations linked to 
expression data in HMCLs and complement other studies in our myeloma 
group. But also a goal was to detect known genetic aberrations in Norwegian 
myeloma patients. More specifically the aims can be divided into the following 
aspects: 
 
Characterization of HMCLs 
 
It is important to choose the most relevant HMCLs to work with. Therefore it is 
important to characterize HMCLs both genetically and also how they respond 
to e.g. different stimulations of cytokines. First and foremost, the HMCLs 
established at our own lab were investigated. When we found OH-2 to be a 
hyperdiploid HMCL, it was important to characterize this cell carefully, so also 
others could fully enjoy the potential of it. Important methods have been, 
among others, FISH, array CGH, SKY, gene arrays, real time RT-PCR and 
proliferation studies. 
  
Are there genetic aberrations that cause the over-expression of 
oncogenes, potential oncogenes or transcription factors in myeloma 
cells? 
 
Many projects in our group are based on microarray data. Known putative 
oncogenes and known oncognes from MM and other cancers, as FGFR3 and 
PRL3, and other potential oncogenes, as BCL3, were studied. Since MM often 
has translocations and genetic aberrations, it was a goal to see if the 
overexpression of some of these genes were caused by translocations or 
amplifications.  
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Study of genetic aberrations in Norwegian MM patients 
 
Unfortunately MM is a very heterogeneous genetic disease. Interphase FISH 
is the preferred method to detect the known genetic aberrations. In addition to 
detect the most prevalent translocations, we wanted to look at the prevalence 
of some of the less common translocations in the Norwegian patient 
population, and to find out if the Norwegian patients differed from patients 
from other parts of the world. We also wanted to see if we could find 
correlations between genetic aberrations, and other parameters measured at 
time of diagnosis (e.g. β-2 microglobulin, M-component and PC%). Also, a 
part of the study was to make the preparation of cells and the FISH method as 
short, easy and reproducible as possible. 
  
This is a prospective study, and it is not finished. The study started in 2006 
and we decided to include 300 patients. We have only come half way in the 
patient inclusion process, and therefore the data on overall survival, response, 
time to remission and type of treatment has not yet been collected. The aim in 
the end is to see if there is any correlation between genetics, clinical findings 
at diagnosis, treatments, time to relapse and overall survival in the Norwegian 
MM patients. Because this is a prospective study we do not report other 
findings than what were measured at the time of diagnosis. 
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3. SUMMARY OF PUBLICATIONS AND MANUSCRIPTS 
 
3.1 Paper I 
 
OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a 
complex translocation juxtaposing MYC near MAFB and the IGK locus 
 
Despite the heterogeneity, MM can be classified into two major groups: 
hyperdiploid HRD tumors with 48-74 chromosomes, which typically have extra 
copies of at least four of the eight odd numbered chromosomes 3, 5, 7, 9, 11, 
15, 19, and 21; and non-hyperdiploid NHRD tumors, which usually have IGH 
translocations and 46< and >74 chromosomes. HMCL with a typical HRD 
phenotype was lacking, and this made the characterization of OH-2 even 
more interesting. The OH-2 HMCL is derived from extramedullary myeloma 
(EMM), and retains the same HRD phenotype as the EMM tumor, with extra 
copies of chromosomes 3, 7, 15, 19, and 21 as demonstrated by the array 
CGH. This provides a unique example of an HMCL and the corresponding 
primary tumor that share the same HRD phenotype. Spectral Karyotyping 
shows the same HRD phenotype in the HMCL. We also did a microarray of 
the HMCL to look at the expression of genes and compare it to a panel of 47 
other HMCLs. High expression of cyclin D2, MAFB and MYC were striking 
findings, which were also confirmed by realtime RT PCR on the primary tumor 
material. This expression we eventually found out was caused by a complex 
translocation. The IGK enhancers had been translocated to MYC on 
chromosome 8 and also juxtaposing MAFB on chromosome 20 to the 
enhancers. The breakepoints were identified by high density array CGH. As a 
result of this analysis, we identified breakpoints, manifested by an 
approximately 30% decrease in copy number, involving all three loci: 685 kb 
telomeric of MYC; 138kb centromeric of MAFB; 10kb centromeric and 18 kb 
telomeric of the 3’ kappa enhancer. These results indicate that the 3’ kappa 
enhancer effectively is inserted between the MYC and MAF genes, so that 
both genes can be dysregulated by the same enhancer element.  
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3.2 Paper II 
 
FGFR3 is expressed and is important for survival in INA-6, a myeloma cell line 
without a t(4;14). 
 
FGFR3 is an oncogene dysregulated by the t(4;14) in myeloma cells, and is 
not usually expressed without this translocation. In INA-6 we discovered an 
amplification of the FGFR3 locus by FISH. This amplification did not involve 
any immunoglobulin loci. By array CGH we discovered that the area of 
chromosome 4 from 4p15.32 to the telomere of the p-arm was amplified. This 
was in concordance with the extra copy found on metaphase FISH. This extra 
copy probably causes the expression of FGFR3 in the cells that we 
demonstrated by RealTime-PCR and Western blot. To find out if the FGFR3 
was important for INA-6 we used the small FGFR3 inhibitors SU5402 and 
PD173074. Both decrease the proliferation and enhance apoptosis in INA-6, 
which indicate that FGFR3 not only can be present, but also be important 
even when the t(4;14) is not present in the cells. 
 
 
3.3 Paper III 
  
Overexpression and involvement in migration by the metastasis-associated 
phosphatase PRL3 in human myeloma cells 
 
Numerous cytokines are known to support growth and survival of MM cells 
and there is likely to be redundancy in the signal. Attempts to block one signal 
will be compensated by other signals and we hypothesized that knowing the 
common genes upregulated by several cytokines would lead us to possible 
future targets. Preliminary microarrays showed that a limited number of genes 
were upregulated after cytokine stimulation in myeloma HMCLs OH-2 and IH-
1. Phosphatases of regenerating liver (PRL phosphatises)-3 was one of these 
genes. PRLs constitute at class of small phosphatases with possible 
oncogenic activity. The PRL3 is known as a metastasis-associated 
phosphatase, and several reports show its importance in cancer cell invasion 
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and migration. Since cell migration is one of the processes fundamental to 
MM cell invasion and dissemination, we decided to look closer at PRL3 in 
MM. We show here for the first time, that PRL3 expression, demonstrated at 
mRNA and protein level, was increased in several MM HMCLs when 
stimulated with mitogenic cytokines. Also a large cohort of MM patients 
expressed PRL3 at higher levels than normal PCs. Because amplification of 
PRL3 has been associated with increased expression in other cancers, we 
used FISH to detect the copy number in the HMCLs. There are HMCL with 
many copies of chromosome 8/PRL3, but OH-2, which has the highest 
expression of PRL3, had an apparent normal chromosome 8/PRL3 copy 
number. However, in RPMI-8226 we found an extra copy of the PRL3, which 
might be the cause of the expression of PRL3 in this cytokine independent 
HMCL. The FISH results indicate that gene expression levels seem to be copy 
number independent. Amplification due to chromosome copy numbers does 
not correlate with gene expression levels in the MM cell lines. Most likely, 
other mechanisms are involved in most of the up-regulation of PRL-3 
expression. Immunohistochemistry on MM patients detected PRL3 protein in 
18 out of 20 patients. In OH-2 the PRL3 was detected by anti-PRL3 staining to 
cycle between the cytosol and the nucleus in a cell-cycle dependent way. 
PRL3 was predominantly nuclear localized in G0/G1-phase and exclusively 
staining in the cytoplasm in the G2M phase. The same was also shown in 
patient sample. Downregulation of PRL3 expression by siRNA reduced SDF-1 
-induced migration in the INA-6 cells, but had no effect on the cell cycle 
distribution or cell proliferation. Taken together these data suggest that PRL3 
is one of the proteins translated as a response to several mitogenc cytokines 
and that it might have a role in migration also in MM cells. Several protein 
tyrosine phosphatases seem to be attractive drug targets in cancers PRL3 
could be a molecular target in subgroups of patients with MM. 
 
3.4 Paper IV 
 
High expression of BCL3 in human myeloma cells is associated with 
increased proliferation and inferior prognosis. 
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This paper started with the same hypothesis as Paper III i.e. that intracellular 
signals generated by cytokines known to be important for growth and survival 
of myeloma cells, target common genes which may be important node 
molecules in myeloma pathogenesis. BCL3 was one of a limited number of 
genes that were activated in the IH-1 and OH-2 cell lines in response to all 
cytokines analyzed. BCL3 is located at 19q13, and is a putative oncogene 
encoding BCL3 that belongs to the inhibitory ĸB (iĸB) family. The i-ĸB proteins 
modulate the DNA-binding activity of NFĸB, a family of transcription factors 
involved in apoptosis and cell growth. Activation of NFĸB is implicated as an 
important mechanism for the development of anti-apoptosis and drug 
resistance in MM. Depending on context, BCL3 either activates or inhibits 
NFĸB-dependent gene transcription through interactions with homodimers of 
NFĸB, p50 or p52. We found in a large cohort of myeloma patients, that Bcl-3 
was over-expressed in MM cells from a subset of MM patients, and that high 
expression level on GEP by the time of diagnosis is associated with the 
proliferation subgroup of patients with an inferior prognosis. Furthermore, 
expression of BCL3 in HMCLs induced by growth promoting cytokines as IL-6, 
IL-21 and TNF-α is associated with increased proliferation of the cells. The 
array data was verified with RT-PCR in a small material with randomly 
selected patients, and BCL3 was also detected at the protein level, both with 
immunohistochemistry and Western blot. Because BCL3 first was identified 
through its involvement in the t(14;19)(q32;q13) in B-cell chronic lymphocytic 
leukemia we also wanted to check if MM patients had an aberration in the 
locus of BCL3. We used a split probe and interphase FISH, and found that 
there was an unbalanced translocation in one out of the 19 randomly picked 
patients investigated. Also, four of the patients had an extra copy of the gene.  
In conclusion, we here showed for the first time that BCL3 is present in a 
subset of myeloma patients and that high expression at diagnosis is 
associated with inferior prognosis. We have not shown that BCL3 is an 
independent adverse prognostic factor in myeloma; however we found that 
BCL3 is a common target gene for several growth-promoting cytokines in 
myeloma cells. Taken together, this may indicate a potential oncogenic role 
for BCL3 in MM, but further studies are needed to clarify this. 
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3.5 Paper V  
 
Genetic aberrations in Norwegian myeloma patients 
-a study based on interphase FISH on newly diagnosed patients from 2006-
2008. 
 
This manuscript is a preliminary report of the findings in a so far three year 
long study. The aim has been to screen the Norwegian MM patients and look 
at genetic aberrations by interphase FISH. This is a prospective study, and we 
intend to include 300 patients before the final report will be given.  
 
We analyze 139 MM patients IGH translocations by break-apart strategy and 
looked at the specific primary IGH translocations t(4;14), t(11;14), t(6;14) and 
t(14;16). All patients were also analyzed for del13 and del17. Up until now we 
have found an IGH translocation incidence that is a bit lower than some others 
have published (41% versus 60% in published studies). However, the 
prevalence of t(11;14) and t(4;14) is approximately the same as others have 
reported with an incidence of 16% and 12% respectively. The incidence for 
t(6;14) and t(14;16) are low, which might be caused by the lack of material for 
some patients. Deletion in chromosome 13 and 17 were present in 30% and 
17% respectively. The del13 frequency is lower than others have reported, 
and del17 frequency is approximately the same as others have reported. 
There was no significant correlation between the specific IGH translocations 
and the deletions in chromosome 13 and 17. We did however find a significant 
correlation between del13 and del17. Del13 was seen in 12 patients (50%) of 
the 24 patients with del17, and in 31 (27%) of the 115 patients without del17. 
There were no significant correlations between clinical findings and genetic 
aberrations. The establishment of the method and an estimate of the 
prevalence of genetic aberrations in myeloma patients in Norway, may have 
significant implications for the future treatment strategy.  
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4. GENERAL DISCUSSION 
4.1 Methodological considerations 
4.1.1 HMCLs –Are they a good model for the MM disease? 
 
Doing basic myeloma research usually means doing experiments with 
HMCLs. A lot of conclusions have been drawn based on observations from 
experiments with these HMCLs grown in monocultures in the laboratories. 
There are more than a hundred HMCLs around the world, and they are 
important tools in the study of MM 94. Most of the genetic abnormalities in the 
HMCL are still the hidden secrets of the cells’. But the information of IGH 
translocation status and chromosome copy number is available for the most 
commonly used HMCLs 52. Also the Multiple Myeloma Genomics Portal 
(MMGP) provides information from studies from different myeloma research 
groups (http://www.broad.mit.edu/mmgp/pages/publicPortalHome.jsf). GEP 
and CGH array results for a wide range of HMCLs and patients are available 
at MMGP.  
 
HMCLs are not fully representative of MM. Some of the translocations are 
more common in HMCLs compared to MM patients. t(4;14) is present in ~25% 
of HMCLs versus ~15% of MM patients. t(14;16) is present in ~25% of HMCL 
versus only ~5% of MM patients29. This discrepancy may reflect the more 
aggressive disease conferred by this t(14;16) translocation, and thereby 
making it easier for the cells to grow in vitro. The difference between the 
prevalence of the translocations in the HMCL versus MM patients will however 
be smaller if one takes into consideration that only approximately half of the 
MM patients are represented with HMCLs. This is because most of HMCLs 
are derived from specimens from patients belonging to the NHRD MMs. The 
bias that most HMCLs are from NHRDs has to be considered when HMCLs 
are used as models of the human disease29. It appears that NHRDs more 
likely become independent of their environment compared to HRDs, and this 
confers a more aggressive disease allowing some NHRDs to grow in vitro. 
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The disconcordance between the HMCLs and the MM patients is a major 
concern. How well do the HMCLs represent the vide range of MM patients, 
especially since there is a lack of HRD HMCLs? And how well do the HMCLs 
represent the BM tumors in the MM patients. 
 
To discuss the last question first: the HMCLs’ originality. How much does the 
cell change when grown in vitro for several years-not to say decades? It is 
difficult to grow primary cells more than a couple of weeks in the lab, even 
with addition of stromal cells and mitogenic cytokines. Also, most HMCLs are 
from patients with relapse and/or extramedullary disease94,95. When 
establishing HMCLs there is also a clonal selection of one or more clone of 
the cells that proliferate more rapidly96. The HMCLs can therefore be 
considered to represent the most malignant end-stage PCs with multiple 
genetic abnormalities21,22. Also it is worth noticing that the same HMCLs used 
at different laboratories in the world might not be identical (personal 
communication M Kuehl). It is left to find out if this is due to for instance 
contamination, mislabelling or mutations during culture. However, on the 
positive side: our experiment with the HMCL OH-2 (paper I) showed only a 
really small difference between the primary cells and the HMCL on CGH 
array. The differences were a small deletion on 10q and an amplification on 
8q in the OH-2 HMCL, which were not present in the primary cells. These 
aberrations might have occurred in vitro, but they could also have been 
present in a small fraction of the primary cells, and been selected during 
culturing. 
 
There are hardly any HMCLs representing the huge hyperdiploid MM patient 
group, and not many HMCLs without IGH translocations. There have been 
attempts to describe hyperdiploid cell lines, and Li et al. described two stromal 
dependent hyperdiploid HMCLs without IGH translocations97. Although, I am a 
bit reluctant to call these two cell lines “true” hyperdiploid when looking at the 
SKY they present. Neither of the cells have more than two of the common 
triploid odd numbered chromosomes. This, and more, has also been criticized 
by others98.  
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I find the fact that there are not available HMCLs for the HRD patient group 
somewhat a problem for the relevance of the MM research being done on 
HMCLs in labs all over the world. Looking at the publicly available array CGH 
at MMGP, it is easy to see that only a few HMCLs have the proper 
chromosome number to be an HRD HMCL. By looking deeper into the arrays I 
would only define the HMCL XG-2 (49 chromosomes) to be a HRD HMCL. 
The other HMCLs with HRD chromosome number (RPMI 8226, 60-62 
chromosomes; JK-6L, 50 chromosomes; KHM-1B, 59 chromosomes; OCI-
MY1, 49 chromosomes) I would not without more considerations put into the 
HRD group. I would like to use RPMI 8226 as an example. Figure 7 shows 
both SKY and array CGH of this HMCL. The HMCL has the correct number of 
chromosomes to be HRD, but when examining the chromosomes it is only 
chromosome 3, 19 (array CGH shows that a piece of one chromosome 19 is 
deleted) and 21 that are the odd number triploid chromosomes. The other 
chromosomes, having more than the normal two copies are even numbered 
chromosomes. Comparing the SKY and the array CGH gives a better picture 
of the real karyotype, because it is not only made from one or a few cells, but 
gives the global copy number in the whole HMCL population at the time of 
harvest. Another feature that gives this HMCL a pro-HRD karyotype, besides 
the total chromosome number, is the fact that it does not have one of the 
primary IGH translocations. It has a t(1;14)(q12;q32) which must be 
considered a non-recurrent IGH translocation, perhaps present at the same 
frequency in both HRD and NHRD 52. The array CGH value zero on the Y-axis 
represents three chromosome copies, evident when compared with the SKY. 
There might be small differences between the SKY and array CGH that may 
also come from the fact that the HMCLs are harvested at different labs (Little 
Rock and Trondheim respectively).   
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Figure 7. Upper figure shows a SKY of HMCL RPMI 8226 (with permission dr J 
Sawyer, UAMS, Little Rock). Lower figure shows an array CGH of RPMI 8226 
(prepared by SH Kresse and L Meza-Zepada)  
 
4.1.2 Isolation of primary MM cells from bone marrow aspirate from 
patients using anti-CD138 antibodies 
 
Since HMCLs are what they are, a model system, it might be important to look 
at responses in freshly isolated primary MM cells. It is believed that 
experiments with primary MM cells in vitro are more relevant to the in vivo 
situation than HMCLs. Even though it is easy to argue that primary cells are 
better to use for experiments than HMCLs, there are also disadvantages. The 
cells have been harvested and have been kept together with e.g. EDTA or 
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heparin. There will also be a time gap between harvest and experiments. It is 
difficult to control if the mRNAs, microRNAs, epigenetics or proteins are not 
disturbed by this handling. Primary cells will always have the heterogeneity 
and it might be difficult to get the same result with samples from different 
patients. At least when the sample is from a newly diagnosed patient, we do 
not know anything about it. This is a good thing in that experiments become 
randomized. However, if the goal is to look at for instance FGFR3 responses, 
it will be more difficult. 
  
Isolation of primary PCs has been done with anti-CD138 antibody from BM 
aspirates from MM patients. In Paper III and IV Macs CD138 coated 
Microbeads (Miltenyi biotech) were used and cells were separated sterile to 
be used also for long time cultures. For FISH and over-night cultures 
RoboSep (Stem Cell technology) automatic CD138 separation of BM 
aspirates was used. With both techniques purity of PCs were determined by 
May Grünvald-Giemsa staining to be on average >97%. With the RoboSep 
separations freshly drawn samples with more than 10 mill cells were usually 
>98% pure and samples sent to us by over night post 95-97% pure. Samples 
shipped over night with fewer cells were usually down to 90% pure, but this 
was still good enough to use for FISH analysis. Samples shipped over night 
were used for FISH analysis only.  
 
4.1.3 FISH 
 
In paper V interphase FISH was done on three different kinds of samples from 
patients. When using BM spreads and mononuclear cells it was important to 
positively select the PCs with antibodies for IGK and IGL. This cytoplasmatic 
(c)Ig-FISH works well to separate out the myeloma cells and to only score the 
PC. In some patients the cytoplasmatic staining can be weak, and if the PC% 
in addition is low, the FISH scoring is time consuming, and will not always give 
conclusive results. The introduction of CD138 separation of PCs the FISH 
procedure was considerably improved and less time consuming (Paper V).  
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4.2 Why is it difficult to establish HRD HMCLs? 
 
As already stated, it is difficult to get primary MM cells to grow, and even more 
difficult to establish a HMCL, especially from HRD that miss one of the 
primary IGH translocations. One reason might be that tumors with HRD 
phenotype are more dependent on the microenvironment than cells with 
primary IGH translocations. As we explain in paper I, OH-2 is strictly 
dependent on mitogenic cytokines and on human serum to be able to grow, 
and even then it grows significantly slower than the other HMCLs in our lab. In 
our experience, other IL-6-dependent cell lines become IL-6-independent after 
culture for extended periods, but this has never been seen with OH-2. To be 
able to establish more HRD HMCL, we need to get primary MM cells to grow 
better in vitro. However, even when growing primary cells with human serum 
and a cocktail of mitogenic cytokines, we experience that the cells die after a 
few months.  
 
Less than 10% of EMM are HRD99,100. It is not yet known what makes an 
intramedullary myeloma to become extramedullary. One genetic answer might 
be the acquisition of autonomous CCND dysregulation. One possible 
explanation is that HRD MM tumors, and especially those that ectopically 
express CCND1, are dependent on signals from the bone marrow 
microenvironment to enable bi-allelic expression of a CCND gene. If this is 
true, then progression to independence from the bone marrow 
microenvironment might require an alternative mechanism to dysregulate a 
Cyclin D gene. It has been proposed that CCND is dysregulated in all MGUS 
and MM, either by a translocation or by bi-allelically expression in many HRD 
tumors. The mechanism for this bi-allelically expression is still to be 
determined26. Perhaps OH-2, and also RPMI 8226 and XG-2, have 
accomplished CCND expression by a genomic rearrangement that 
dysregulates MAF or MAFB, both of which increase expression of CCND2. 
We need to answer at least two important questions regarding HRD MM 
tumors. First, what is the mechanism by which CCND1 is bi-allelically 
dysregulated in HRD MM tumors? Second, why do HRD MM tumors so 
infrequently progress to EMM tumors or HMCL that express CCND1? 
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4.3 Is FGFR3 important in myeloma? 
 
FGFR3 is one of the genes affected by the t(4;14). It was the finding of 
ectopically expressed FGFR3 in MM that gave the first indication that FGFR3 
was a potential oncogene101. In MM, activating mutations in FGFR3 are 
present in about 1/3 of t(4;14) patients and half of the HMCLs102. It is reported 
that RAS and FGFR3 mutations are mutually exclusive. Since both RAS and  
FGFR3 activation, lead to MAPK activation, they may induce overlapping 
oncogenic signaling103. This is in concordance with our findings in HMCLs IH-
1 and INA-6. Both IH-1 and INA-6 have no mutations in FGFR3, but NRAS is 
mutated in codon 12 in both HMCLs (unpublished data). In paper II we 
describe that INA-6 has expression of FGFR3 without t(4;14) and that FGFR3 
might be important for the myeloma cells. Acidic-Fibroblast growth factor 
stimulated IH-1 and INA-6 have phosphorylated ERK1 and ERK2 detected by 
WB. Adding the inhibitors described in paper II the phosphorylation is only 
partly taken down compared to cells not treated with the inhibitors 
(unpublished data). This is expected with the mutated NRAS present. We 
believe that FGFR3 contributes to proliferation in INA-6 and IH-1 and it 
deserves to be more looked into. 
 
4.4 The relevance of doing FISH analysis on every myeloma 
patient 
 
Genetics as a prognostic tool is already established. NHRD patients have 
poorer survival than HRD and del17, t(4;14) and t(14;16) have poorer survival 
than other genomic aberrations20,29. We established FISH to be able to give 
the service to hospitals in Norway. 
 
Some studies evaluate the genetic impact of prognosis and outcome after 
different treatment strategies. A study by Gertz et al. showed that when high 
dose therapy with stem cell support was used, t(4;14) patients had a 
progression-free survival of 8.2 months compared to 20.1 months for t(11;14) 
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patients. For patients with del17 progression-free survival was 8.7 months. 
This suggest that high-dose therapy with stem cell support might not be the 
best therapy for these patients45. In the UAMS total study II it was seen that 
patients with non-favorable cytogenetics/GEP have greatest benefit from 
thalidomide with a significantly higher overall and event free survival 
compared to favorable cytogenetics/GEP patients104. Also Chng et al.105 
suggested that the various genetic subtypes at diagnosis and relapse appear 
similar, but at the same time the prognosis of some genetic subtypes, like 
t(11;14), might be worse at relapse. Whereas for instance HRD patients 
appeared to behave similarly, both at diagnosis and at relapse. They therefore 
suggested that patients with t(11;14) should be treated more aggressively 
when relapsed. They also report that t(4;14) patients benefitted from 
bortezomib, improving the prognosis of these patients to that of genetic 
subgroups with better prognosis. All in all this states the fact that different 
treatment strategies may be needed for newly diagnosed and relapsed 
patients, even in the same genetic group105. Bortezomib also seemed to 
exacerbate some of the poor prognosis in del13 patients106,107.  
 
It is difficult to draw uniform conclusions from the studies that have been 
published until today. We have still not come so far that there are tailored 
treatments for patients with different translocations or other genetic 
aberrations. But it is a hope for the future that such treatments will come. I am 
hoping for a large study that correlates the outcome of treatments with genetic 
aberrations. Perhaps as Chng et al. reports that t(4;14) patients go from poor 
to a more average prognosis, treated with bortezomib, and perhaps patients 
with other genetic abnormalities like the del17 could benefit from some other 
drugs? I am looking forward to read about a large prospective study that 
incorporates genetic aberrations to treatment strategies, and I hope it will 
come soon. Some of the motivation, studying genetics in MM, is that it 
somehow eventually can help the patient to be treated fully, at least a longer 
event free survival and a better quality of life with managing the disease. So, I 
think is not unreasonable to do FISH on all patients, but I am not sure we 
know the full potential of it yet. 
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5. CONCLUSION AND FURTHER THOUGHTS 
 
As with all research -the more you find out -the more questions are asked. 
This thesis answers some questions, but there are still more to be asked. In 
this study we provide further insight in the complex genetic field of the 
myeloma cells, particularly the HMCLs. More specifically, we have revealed 
the OH-2 cells’ hidden hyperdiploid phenotype and thereby given a long 
sought hyperdiploid MM model system in vitro. We will however not stop here, 
and hopefully we will reveal why OH-2 HMCL are strictly dependent on human 
serum. We hope that an answer to that might help us to establish more 
HMCLs from HRD patients. We have also revealed that more specific genes 
like the PRL3, FGFR3 and BCL3 can be amplified or translocated, even 
though the specific mechanism behind it is not clear. It has also been 
interesting to screen Norwegian MM patients for genetic aberrations. Because 
this study is not completed, this will also be a study for the future. The biggest 
thoughts for future basic research are perhaps the questions I ask in the 
discussion about HRD MM, and I hope to be able to investigate the secrets of 
the HRD MM further. 
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Abstract 
 
Multiple myeloma (MM) can be classified into two groups: hyperdiploid (HRD) tumors 
(48-74 chromosomes), which typically have extra copies of chromosomes 3, 5, 7, 9, 
11, 15, 19, and 21; and non-hyperdiploid (NHRD) tumors, which usually have 
immunoglobulin heavy chain (IGH) translocations.  The OH-2 HMCL was derived 
from extramedullary myeloma, and retains the same HRD phenotype as the primary 
tumor, with extra copies of chromosomes 3, 7, 15, 19, and 21. This provides a unique 
example of an HMCL and the corresponding primary tumor that are shown to share 
the same HRD genotype. The OH-2 HMCL and the primary tumor cells both express 
high levels of Cyclin D2, but do not have an IGH or IGL translocation. Instead, both 
have a complex translocation in which a 28 kb sequence, including the IGK 3’ 
enhancer, is inserted between MYC and MAFB, resulting in dysregulation of both 
oncogenes.  These data, together with published results for two other HMCL, suggest 
that secondary MAF/MAFB translocations provide one mechanism that enables HRD 
tumors to overcome microenvironment dependence, enabling an intramedullary 
tumor to progress to an extramedullary phase from which an HMCL sometimes can 
be generated.  
 
Introduction 
  
Multiple myeloma (MM) is a neoplasm of long-lived bone marrow plasma cells 1. Both 
MM and pre-malignant monoclonal gammopathy of undetermined significance 
(MGUS) can be separated into two groups that are distinguished by chromosome 
content 2,3. Approximately 50% of tumors are hyperdiploid (HRD), and contain 48-74 
chromosomes, typically with extra copies of at least four of eight odd-numbered 
chromosomes (3, 5, 7, 9, 11, 15, 19, 21). The remaining tumors are non-hyperdiploid 
(NHRD), containing <48 and/or >74 chromosomes. These two groups are further 
dustinguished by IGH translocations with five reciprocal partners (4p16, 
MMSET/FGFR3; 11q13, Cyclin D1; 6p21, Cyclin D3; 16q23, MAF; and 20q12, 
MAFB) that are present in about 70% of NHRD tumors but only about 15% of HRD 
tumors. It appears that recurrent IGH translocations and hyperdiploidy are primary 
events that occur early in pathogenesis. Secondary translocations, which include 
most IGH rearrangements not involving one of the five recurrent partners, most IGL 
and IGK rearrangements, and MYC rearrangements, appear to contribute equally to 
progression of both HRD and NHRD tumor 4. 
 
Despite a low proliferation index, there is increased expression of one of the three 
CYCLIN D genes in virtually all MGUS and MM tumors, suggesting that this is a 
unifying and early oncogenic event. Primary translocations can directly dysregulate 
Cyclin D1 or Cyclin D3, or indirectly dysregulate Cyclin D2 (transcription target of maf 
proteins and unknown mechanism for MMSET/FGFR3 translocation). The HRD 
tumors lacking a primary translocation mostly express increased levels of Cyclin D1 
(~70%), Cyclin D1+Cyclin D2 (~10%), or Cyclin D2 (~20%) compared to normal 
plasma cells 5.   
  
In contrast to intramedullary MM tumors, most (~60%) extramedullary (EMM) tumors 
have one of the recurrent IGH translocations, and less than 10% are HRD 6,7. 
Similarly, human myeloma cell lines (HMCL) are derived almost exclusively from 
EMM tumors, mostly are NHRD and usually have one of the recurrent IGH 
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translocations (~75%), suggesting that intramedullary HRD tumors are less likely to 
develop into EMM tumors or HMCL 8. There are no known examples of HMCL that 
have been shown to be derived from a primary tumor that has a HRD phenotype and 
does not have a recurrent IGH translocation 9.  
 
OH-2 is a stroma-independent HMCL derived from an EMM tumor that developed 
following treatment and progression of an intramedullary MM tumor  10. Previously, it 
was reported that the OH-2 HMCL, which has a doubling time of about four days, is 
completely dependent on interleukin (IL)-6, and human serum for stromal cell 
independent growth in culture. In this paper we report that the OH2 HMCL retains the 
same HRD genotype as the EMM tumor cells. We also characterize its chromosomal 
composition, some genetic anomalies, and some of its growth characteristics. 
 
Material and Methods 
 
Cell line, OH-2 
The HMCL OH-2 was established in 1991 at St. Olavs University Hospital from 
pleural fluid of an MM patient in terminal stage of the disease 10. The cell line is 
cultured in RPMI 1640 (Gibco, Paisley, UK) with L-glutamine (100 µg/ml) and 
gentamicine (20µg/ml), supplemented with 10 % human serum (AIT, St. Olavs 
University Hospital, Trondheim, Norway) and IL-6 2 ng/ml, in a humidified 
atmosphere containing 5 % CO2 at 37°C. For an experiment to optimize growth 
condition for the HMCL, OH-2 was grown in various combinations, as denoted in 
legend to Fig 7.  
 
Primary cells from the patient who gave rise to the OH-2 cell line 
Cells from the pleural fluid of the patient who gave rise to the OH-2 cell line were 
separated by lymphoprep centrifugation and kept in RPMI 1640 with 10% DMSO and 
30% fetal calf serum (FCS) in liquid nitrogen, frozen at the day of sampling. Cells 
were thawed, and RNA and DNA were isolated shortly after thawing. The cell 
suspension contained 90-95 % pure plasma cells. These cells are further called 
primary OH-2 cells. An epon-embedded biopsy taken 10 months before the pleura 
fluid harvest was unfortunately not applicable for either DNA analysis or 
immunohistochemistry. 
 
Other HMCLs and culture conditions 
JJN-3 11, ANBL-6 (gift from Dr D Jelinek, Mayo Clinic, Rochester, MN) RPMI-8226 
(from America Type Culture Collection, Rockville, MD) and INA-6 (gift from Dr M 
Gramatzki, Erlangen, Germany) are maintained as previously described 12,13. 
   
Fluorescence in situ hybridization (FISH) 
Probes for FISH were made from Bacterial Artificial Chromosome (BAC) clones 
containing the desirable genomic region covering loci 2p11, 4p16, 11q13, 14q32, 
16q23, 20q12 and 22q11. In addition a break-apart probe for IGK was purchased 
from Dako (Dako Cytomation, Glostrup, Denmark). Supplementary Table A shows 
probe loci and clones. Probes for 4p16, 11q13, 14q32 and 16q23 were gifts from R. 
Fonseca, probes for 20q12 and IGK from M. Kuehl, the rest was purchased from 
Invitrogen. Whole Chromosome Paint (WCP) probes for chromosome 2, 14, 20 and 
22 in aqua, and chromosome 8 in green (Applied Spectral Imaging, Micro System 
AB, Spånga, Sweden) were used to verify genes on their respective chromosomes. 
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CEP 2 and CEP 8 SpectrumAqua were used to label the centromeric region in the 
chromosomes (Vysis, Abbot Laboratories, Des Plaines, IL). FISH with WCP and in-
lab LSI probes were used as follows: 2 µl LSI probe in water + 2 µl WCP with 6 µl LSI 
hybridization buffer (Vysis). For IGK 2 µl WCP 2 and 8 µl of IGK probe mix (Dako) 
were used. Metaphase spreads was made according to standard methods 14. The 
metaphases were prepared at least one week prior to use without additional heating 
or chemical treatment. Method and microscopy as described earlier 12. 
 
Karyotyping 
Conventional cytogenetic methods Giemsa-banding (G-banding) and spectral 
karyotyping (SKY) were performed after standard procedure as described 15. 
 
Microarray-based comparative genomic hybridization (array CGH) 
The genomic microarray was done using 500 ng genomic DNA sample from OH-2 
cell line and primary cells after methods as described 16,17.  
 
Southern Blot for IGH, IGK and MAFB 
Southern Blots were performed on genomic DNA from OH-2 to look for IGH 
illegitimate switch recombination fragments, as previously described 18.  
 
Gene expression profiling 
Total RNA was profiled and analyzed as described previously (8,24), using Affymetrix 
HG-U133_Plus_2.0 Chips (Affymetrix, Santa Clara, CA).  Profiling data were 
available for 559 newly diagnosed MM tumors (GEO accession GSE2658; 
http://www.ncbi.nlm.nih.gov) and 46 HMCL 
(http://www.broad.mit.edu/mmgp/pages/publicPortalHome.jsf).  The expression of 
individual genes was normalized to the median expression of that gene in the entire 
sample set of 559 MM tumors and 47 HMCL. A MAF index (MAFI) was calculated 
from the median expression of 50 genes that are up-regulated in the MAF group 19, 
and the samples in Table 1 were arranged in descending order, based on the value 
of the MAFI.  Other probe sets used in Table 1 included: CCND1, 208711_s_at; 
CCND2, 200951_s_at; CCND3, 201700_at; FGFR3, 204379_s_at; MMSET, 
223472_at; MAF is the median of 206363_at, 209347_s_at, 209348_s_at, and 
229327_s_at; MAFB is the median of 218559_s_at and 222670_s_at; and MYC is 
202431_s_at.  A proliferation expression index, P(12), was calculated from the 
median expression of twelve genes that are included in a proliferation signature 8. 
 
Cell proliferation assay 
Cell proliferation assay was performed as previously described 20. The cells were 
stimulated with one or several of these cytokines: 1 ng/ml recombinant human IL-6, 
200 ng/ml a proliferation inducing ligand (APRIL), 200 ng/ml B-cell activating factor 
(BAFF), 100 ng/ml IGF-1, 10 ng/ml IL10, 20 ng/ml IL15, 10 ng/ml IL-21 (R&D 
Systems, Abingdon, UK), 10 ng/ml TNF (Genetech, South San Fransico, CA) and 
100 ng/ml hepatocyte growth factor (HGF) purified in our own laboratory 21. The 
counts per minute (cpm) obtained was normalized to the serum control sample. 
 
Real-time RT-PCR on Cyclin Ds, and MAFB  
Total RNA from OH-2, INA-6 and ANBL-6 cells cultured as described, was isolated 
using RNeasy Mini Kit (Qiagen, Crawley, UK), with DNase treatment. cDNA was 
made from RNA using SuperScript®III First Strand Synthesis System for RT-PCR 
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(Invitrogen). Cyclin D1-3 and MAFB TaqMan primers, (HS00765553_A1, 
HS00277041_A1, HS01017690_g1 and HS00271378_s1 respectively, TaqMan, 
Gene Expression Assays, Applied Biosystems, Foster City, CA), were used to detect 
cyclin Ds and MAFB expression. A control without reverse transcriptase added was 
used for the one exon gene MAFB to make sure there was no genomic DNA 
contamination. The comparative Ct-method was used for quantization with GAPDH 
(HS99999905_m1) as housekeeping gene.  
 
Sequencing of TP53 and RAS 
TP53, NRAS, HRAS or KRAS2A/B cDNA was PCR-amplified and sequenced to 
examine for nucleotide mutations.  All RT-PCR reactions were purified with QIAquick 
PCR Purification Kit (Qiagen) and directly sequenced using BigDye Terminator v1.1 
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA), DyeEx 2.0 Spin Kit 
(Qiagen) was used to purify the sequencing reaction that was analysed on ABI3100 
Genetic Analyzer (Applied Biosystems). Details of primers and primer position are 
listed in Supplementary Fig B-C. 
 
Results 
 
OH-2 does not have an IGH translocation 
Using a split probe strategy on metaphase spreads, there was no dissociation of the 
centromeric and telomeric probes for the IGH, IGK, or IGL loci (Figs 1a-c). OH-2 was 
also tested with dual fusion probes for the recurrent IGH translocation partner loci at 
4p16, 6p21, 11q13, 16q23, and 20q12, but no cryptic translocation involving IGH with 
any of these loci was detected (not shown). WCP probes confirmed that the IGH, 
IGK, and IGL loci were on chromosomes 14, 2, and 22, respectively. However, it was 
noted that there was a complex translocation near the IGK locus on chromosome 2, 
with both IGK probes localizing to der(2) (Fig 1b).  Southern blots identified 4.4 kb 
and 4.7 kb Hind III 5’ switch mu/3’ switch gamma legitimate switch recombination 
fragments, consistent with normal rearrangements involved in expression of IgG by 
the OH-2 tumor cells (not shown), but no illegitimate switch recombination fragments 
were detected.  
 
Identical hyperdiploid chromosome content of OH-2 cell line and primary tumor 
Conventional G-banding and SKY analyses (Fig 2a-b) revealed the presence of 48-
51 chromosomes, with trisomies of chromosomes 3, 7, 15, 19, and 21, in the OH-2 
HMCL. In addition to aneuploidy, ten translocations and one large interstitial deletion 
were identified (Fig. 2a-b). Unfortunately, karyotypic analyses are not available for 
either the initial intramedullary MM tumor or the EMM tumor. Therefore, array CGH 
was performed to check for additional chromosomal aberrations in OH-2, and to 
compare the OH-2 HMCL and the EMM tumor. The OH-2 HMCL and OH-2 primary 
tumor showed virtually identical array CGH patterns apart from a 10q deletion and 
amplification of a portion of 8q that were uniquely present in the HMCL (Fig. 2c). 
Significantly, array CGH analyses confirmed in both the cell line and tumor the extra 
copies of the five odd-numbered chromosomes, and also chromosome 14, which 
were confirmed by additional FISH analyses (not shown). Finally, the array CGH and 
karyotypic analyses also verified loss of one copy of chromosome 13, as well as loss 
of 1p and gain of 1q sequences. 
 
OH-2 cell line and primary tumor cells express a high level of MAFB RNA 
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The gene expression profile of the OH-2 cell line was determined using an Affymetrix 
HG-U133_Plus_2 chip, and compared to results that are available for 46 other 
HMCL. Selected results are shown in Table 1. Strikingly, the OH-2 HMCL expresses 
MAFB RNA at a level that is higher than the three HMCL (SACHI, EJM, SKMM-1) 
that have t(14;20) translocations. Consistent with the expression of high levels of 
MAFB, the OH-2 cells express extremely high levels of Cyclin D2 RNA, low levels of 
Cyclin D3 RNA, and very low levels of Cyclin D1 RNA. Real time PCR assays 
confirmed that the OH-2 primary tumors cells also express high levels of MAFB and 
Cyclin D2 but low levels of Cyclin D1 RNA (Fig. 3).  Significantly, the OH-2 HMCL 
has a MAF expression signature that places it among the 42 MM tumors and 14 other 
HMCL that express high levels of MAF or MAFB RNA (Table 1 plus Materials and 
Methods). In addition to Cyclin D2, some other apparent MAF targets with expression 
levels at least tenfold above the median of the tumors and cell lines include integrin 
beta7, ARK5, and MRF-1. Finally, the MYC RNA level in the OH-2 HMCL is in the 
highest quartile of the 47 HMCL (Table 1). 
 
MAFB and MYC are juxtaposed by a complex translocation process involving IGK 
In view of the high level of MAFB expression in OH-2, we suspected the 
translocations involving chromosomes 2, 8, and 20, as der(20)t(2;20)(p11;q12), 
der(8)t(8;20)(q24;q12)t(8;20)(q24;q12) or der(8)t(8;20)(q24;q12) and 
der(2)t(2;8)(p11;?q24) might be the cause.  To determine if there is a rearrangement 
near MAFB, we performed FISH with a MAFB probe, as well as nearby centromeric 
and telomeric probes, in combination with WCP 2, 8, and 20, and also CEP probes 
for chromosomes 2 and 8 (Fig. 4c,e). MAFB is normally located at 20q11.2-q13.1 
(http://www.genecards.org). There is one intact copy of chromosome 20 (Fig 4b), but 
the MAFB locus was also translocated to chromosome 8. There were two clones of  
the HMCL, with either der(8)t(8;20)(q24;q12)t(8;20)(q24;q12) (~30%) or 
der(8)t(8;20)(q24;q12) (~70%), each paired with a normal chromosome 8. The 
translocated MAFB was localized at the 8;20 junction on der(8), or on both 8;20 
junctions on der(8)t(8;20)t(8;20) (Fig 4e-f). Probes that were about 400 and 700 kb 
centromeric to MAFB were present only on der(20), and a probe that was about 1100 
kb telomeric to MAFB was present only on der(8) (Table 2). Thus the breakpoint on 
chromosome 20 apparently occurred less than 400kb centromeric to MAFB. A MYC 
probe hybridized to the 8;20 junction on der(8) or to both 8;20 junctions on 
der(8)t(8;20)t(8;20), but not to der(2)t(2;8) (Fig 4f-g). Therefore, MYC and MAFB are 
juxtaposed on both der(8). Despite the lack of a Vkappa/Ckappa split by conventional 
FISH analyses (Fig 1b) we suspected that a Ckappa enhancer was juxtaposed to 
MAF and MYC.  By using a relatively small BAC that included intronic and 3’ 
enhancer sequences from the IGK locus, we detected a hybridization signal on der 
(8)t(8;20)(q24;q12) (Table 2). A similar result was obtained with a pair of PCR probes 
that included 25 kb of sequences that encompass the intronic enhancer, the 3’ 
enhancer, and the 3’ kappa deleting element (Fig 4d) (Table 2). The co-localization of 
one or both kappa enhancers together with MYC and MAFB was confirmed, and is 
present in all t(8;20) junctions (Fig 4d).  Interphase FISH analyses confirmed a 
MAFB/MYC fusion signal, both in the cell line and in primary tumor cells, thereby 
demonstrating that the close (<500 kb) juxtaposition of these two genes occurred in 
the patient (Fig 4f-g). The complex der(8)t(8;20)t(8;20) was also present in the EMM 
tumor cells (Fig 4f-g). These and additional FISH mapping studies are summarized in 
Table 2 and Fig 4. 
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Mapping breakpoints near MAFB, MYC, and kappa enhancer by high density array 
CGH. The colocalization of MAFB, MYC, and kappa sequences on both kinds of 
der(8) suggested that breakpoints should be localized telomeric of MYC, on both 
sides of kappa sequences, and centromeric to MAFB (Fig. 5).  The rearrangements 
involving chromosomes 2, 8, and 20 appeared to be balanced in most cells, but a 
partial imbalance was suggested by the duplication of the t(8;20) junction in about 
30% of OH2 cells.  Therefore, high density tiling CGH arrays were designed in an 
attempt to identify breakpoints near the MAFB, MYC, and kappa enhancer 
sequences. As a result of this analysis, we identified breakpoints, as  
manifested by an approximately 30% decrease in copy number, involving  
all three loci: 598 kb telomeric of MYC, 148 kb centromeric of MAFB;  
18.6 kb telomeric and 9.9 kb centromeric of the 3' kappa enhancer. These results 
(Supplementary Figure D) indicate that the 3’ kappa enhancer effectively is inserted 
between the MYC and MAF genes, so that both genes can be dysregulated by the 
same enhancer element.  The combined FISH and array CGH results are consistent 
with sequential translocations as depicted in Fig 5.  
 
Additional genotypic and phenotypic characteristics of OH-2 
The sequence of KRAS was normal, but there was a CAA (GLN) to AAA (LYS) 
mutation in codon 61 of NRAS. Although all but three (KMS-28BM; KMS-28PE; XG-
6) of 46 HMCL either have a mutation in TP53, no or very low expression of TP53, or 
an increased level of MDM-2 expression (M. Kuehl, unpublished), there were no 
sequence abnormalities of TP53 or RNA expression abnormalities of TP53 or MDM-2 
in OH-2. Similarly, although approximate 50% of the 46 HMCL have inactivated either 
p18INK4c or RB1 22, the RNA expression of both of these genes appears to be 
normal in OH-2 (data not shown).  Surprisingly, despite an extremely slow rate of 
growth in culture (below), the OH-2 HMCL has a proliferation expression index of 
18.9, the fourth highest of the 47 HMCL.  
 
Proliferative response to mitogenic cytokines 
We previously published the response of OH-2 to different cytokines, e.g. a 
synergistic response to TNFα and IL-21, an intermediate response to IL-10, IL-15, 
and TNFα alone, and a modest response to IL-2 and IGF-1 20. Although OH-2 has a 
low NF-kappaB index (MK, unpublished), we also wanted to test the TNF analogs 
BAFF and APRIL on OH-2 23,24. Both BAFF and APRIL gave a lower proliferative 
response, as measured with 3H-thymidine incorporation, and did not show any 
synergism with IL-21. This is depicted in Fig 6, which also shows that a variety of 
cytokines can enhance proliferation in OH-2.   
 
Culture requirements for the OH-2 cell line 
The growth of OH-2 is strictly dependent on IL-6 and human serum, although growth 
is extremely slow, with a doubling time of about four days. In an attempt to find a 
more effective way to culture OH-2 we modified ingredients of the medium as FCS 
with various cytokines, FCS concentrations, and advanced RPMI 1640. Fig 7 shows 
a representative selection of the cell counts measured before media was replenished. 
The only condition to keep the cells for long-term was to use IL-6 together with 
human serum. The cells with human serum without IL-6 showed better survival than 
cells with cytokines and FCS, but could not survive for extensive time under this 
condition either. 
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Discussion 
 
Approximately 50% of MM tumors are HRD and do not have one of the five recurrent 
IGH translocations.  However, this phenotype is found in less than 10% of reported 
EMM tumors 6,7.  Significantly, for the very limited number of HRD EMM tumors that 
have been reported, it is unknown whether the corresponding intramedullary MM 
tumor had the same HRD genotype. Similar to EMM, from which virtually all HMCL 
are derived, HMCL only infrequently are HRD in the absence of one of the five 
recurrent IGH translocations 4,25.  For example, of the 46 HMCL (excluding OH-2) in 
Table 1, only ten (22%) do not have one of the recurrent IGH translocations. Five 
(10% overall) of these HMCL have a HRD chromosome content (RPMI 8226, 60 
chromosomes; XG-2, 49 chromosomes; JK-6L, 50 chromosomes; KHM-1B, 59 
chromosomes; OCI-MY1, 49 chromosomes). Unfortunately, it is not known whether 
or not the corresponding intramedullary MM tumor or EMM tumor had the same 
chromosome number as these five HMCL.  
 
As summarized above, the OH-2 HMCL, which was derived from an EMM tumor, 
does not have an IGH translocation and retains the same HRD phenotype as the 
tumor, with extra copies of chromosomes 3, 7, 15, 19, and 21. This provides a unique 
example of an HMCL and the corresponding primary tumor that share the same HRD 
phenotype. However it has a complex translocation involving the IGK locus, which is 
juxtaposed with both MYC and MAFB. The OH-2 HMCL and primary EMM tumor 
expresses very high levels of Cyclin D2 but only low levels of Cyclin D1, consistent 
with the phenotype of the 20% of HRD MM tumors that express increased levels of 
Cyclin D2 but not Cyclin D1 8.  The OH-2 HMCL is similar to the RPMI 8226 HMCL in 
that both have dysregulated MYC through complex translocations events that 
juxtapose MYC with MAFB and IgK or MAF and IgL, respectively 4.  
 
Other notable features of the OH-2 HMCL include the loss of 1p sequences, gain of 
1q sequences, deletion of chromosome 13, and lack of trisomy 11, all of which are 
associated with the poorest clinic outcome amongst the hyperdiploid patient group 
(Carrasco et al). These genetic signatures correspond to the aggressive disease in 
the patient whose malignant cells derived OH-2 cell line 10. Despite an extremely high 
expression proliferation index and dysregulation of MYC, the OH-2 HMCL has a 
doubling time of at least four days when grown in vitro. In this regard, it may be 
relevant that OH-2 is one of the few HMCL that does not have a mutation or markedly 
decreased expression of TP53 or a substantial increase in MDM-2 expression. It is 
also worth noticing the gene expression profile study by Chng et al. that classified 
different clusters of hyperdiploid myeloma patients, where one of the clusters is 
defined by the overexpression of PRL-3, SOCS, HGF and IL-6 genes 26. We have 
recently published that PRL-3 is highly over-expressed in OH-2 12. Other experiments 
in our lab have shown that IL-6 induces transcription of HGF in OH-2 (Hov personal 
communication). 
 
It is a pertinent question why it seems more difficult to establish HMCL from tumors 
that are HRD and lack one of the five recurrent IGH translocations. A reasonable 
answer could be that tumors with this phenotype are more dependent on the 
microenvironment than cells with primary IGH translocations. The strict dependence 
of OH-2 on mitogenic cytokines and on human serum supports this. In addition it is 
worth noticing that OH-2 grows significantly slower than the other HMCLs in our lab. 
 9
In our experience, other IL-6-dependent cell lines become IL-6-independent after 
culture for extended periods, but we have never experienced this with OH-2. Most 
HMCLs reported in the literature grow in medium supplemented with FCS, but OH-2 
cells are impossible to wean from their dependence on human serum, which is 
something that remains to be clarified. Anyway, one way of circumventing the 
problem with establishing similar cell lines might be to use human serum in the 
growth medium. An additional genetic answer to this might be the acquisition of 
autonomous Cyclin D dysregulation. In fact, it is remarkable that all of the six HDR 
HMCL (above) express high levels of Cyclin D2, whereas ~70% of HRD MM tumors 
express increased levels of Cyclin D1 (but not of Cyclin D2) compared to normal 
bone marrow plasma cells 8. Significantly, of two recently reported stromal cell 
dependent HMCL, neither expresses Cyclin D1;  instead, one expresses high levels 
of Cyclin D2 and the other expresses extremely low levels of RB1, perhaps 
eliminating the need for increased expression of a Cyclin D gene 27. One possible 
explanation is that HRD MM tumors, and especially those that ectopically express 
Cyclin D1, are dependent on signals from the bone marrow microenvironment to 
enable bi-allelic expression of a Cyclin D gene. If this is true, then progression to 
independence from the bone marrow microenvironment might require an alternative 
mechanism to dysregulate a Cyclin D gene. Perhaps OH-2, and also RPMI 8226 and 
XG-2, have accomplished this by virtue of a genomic rearrangement that 
dysregulates MAF or MAFB, both of which increase expression of Cyclin D2.   
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Titles and legends to figures 
 
Figure 1.  FISH detects intact immunoglobulin genes 
a-c) Break-apart probes for IGH, IGK and IGL, a-c respectively, were used together 
with WCP for the corresponding chromosome 14, 2 and 22. The yellow co-
localization signal for the immunoglobulin loci indicates co-localization of the probes. 
a) WCP 14 and IGH break-apart probe show no abnormalities. b) WCP 2 and IGK 
break-apart probe suggest no translocation within the IGK locus. On the two 
derivatives involving chromosome 2, both IGK probes remain together near the 
breakpoint on der(2) (Fig. 2b). c) WCP 22 and IGL break-apart probe show no 
abnormalities. (Original magnification 1000x).  
 
Figure 2. The karyotype of OH-2 has a hyperdiploid profile 
a) Representative G-band with karyotype; 48~51<2n>,XX,-1, 
der(1)t(1;3)(q12;q13)del(3)(q24), der(2)t(2;8)(p11;?), +3, der(3)t(1;3)(p22;q21), 
del(6)(q23), +7, der(8)t(8;20)(q24;?q12)t(8;20)(q24;?q12), der(10)t(8;10)(?;q26), -13, 
der(13)(13qter→13p11::1q21→1q41::19?p13), +15, der(16)t(9;16)(?;?), 
der(18)t(1;18)(q21;p11), der(20)t(2;20)(p11;q13), +21, 
der(21)t(1;21)(q21;q22)dup(1)(q21q32)x2 
 b) SKY of the OH-2 cell line. The G-band and the SKY analyses demonstrate the 
aberrations in the OH-2 cell line. The chromosome number and the trisomy 3, 7, 15, 
19 and 21 indicate a hyperdiploid karyotype. c) Array CGH shows the genomic 
aberrations of the OH-2 primary cells (black) and the OH-2 cell line (red) in the same 
plot. Log2 ratios for each of the BACs and PACs are plotted according to 
chromosome position. Log2 values ~ 0.6 indicate one extra copy of the chromosome 
area, and values ~ -1 indicate loss of one copy of the chromosome area. Smoothing 
of the mean of 15 clones is used in this plot. Detailed array CGH in supplementary 
Fig A.  
 
Figure 3. Expression of CCNDs and MAFB mRNA in primary and HMCL OH-2 
The expression patterns of OH-2 primary cells and OH-2 cell line are quite similar. 
Both have high expression of cyclin D2 and low expression of cyclins D1 and D3, but 
with a higher expression of cyclin D3 in the primary sample. INA-6 is a t(11;14) cell 
line and expresses high amounts of cyclin D1. ANBL-6 is a t(14;16) cell line and 
expresses high amounts of cyclin D2. MAFB is almost equally expressed in HMCL 
and primary OH-2 cells. The scale is in log10 and the values are relative quantitation 
based on the delta Ct method (see Methods). Cyclin D3 expression in OH-2 cell line 
was set as 1 and all values are normalized to this. Error bars show standard 
deviation of triplicates. 
 
Figure 4. MAFB and MYC is juxtaposed in a complexed translocation 
a) Normal chromosome 8 with WCP8 in green and MYC red; b) normal chromosome 
20 with WCP20 in aqua and MAFB red; c) MAFB and probes centromeric to MAFB 
localize the breakpoint on der(20); d) Ck Enh is a PCR derived probe covering the 
enhancers in IGK, co-localizes with MAFB and MYC on both junctions on der(8); e) 
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der(8)t(8;20) with MAFB red; f) der(8) is replaced by der(8)t(8;20)t(8;20) in some 
cells, with MYC and MAFB juxtaposed at both 8;20 junctions. This is also detected in 
primary OH-2 cells giving two fusion MYC/MAFB (arrows) signals together with two 
CEP8 and one normal MYC and MAFB signals; g) Most of the cells have only one 
8;20 junction. This is also detected in interphase nuclei with MYC/MAFB (arrow) 
fusion signal both in the HMCL and primary cells. 
 
Figure 5. How did the complex translocation process occur? 
There might have been an initial reciprocal translocation between chromosomes 2 
and 20, which juxtaposed MAFB and the IGK locus on der(2), but without the usual 
split between the two IGK probes. A subsequent reciprocal translocation between 
der(2) and normal chromosome 8 would have generated der(8)t(8;20) and 
der(2)t(2;8), with the IGK sequences localized on der(2), but with co-localization of 
MYC, MAFB, and IGK enhancer sequences on der(8). The der(8)t(8;20)t(8;20) must 
have been generated subsequently by a rearrangement of der(8) that included 
duplication of the 8;20 junction.  See Table 2 and text for further details. 
 
Figure 6. OH-2 responds to a wide selection of cytokines. 
Proliferation measured with methyl-[3H]-thymidine incorporation in DNA in OH-2 cell 
line. Stimulation with different cytokines shows that OH-2 is responsive to a wide 
selection of cytokines, both alone and to different cytokines together with additive or 
synergistic effects. Error bars show standard deviation of triplicates. 
 
Figure 7. Continuously growth of OH-2 HMCL 
OH-2 is a slow growing cell line that is difficult to grow without human serum and IL-
6. The chart shows a “stock experiment” in which different RPMI media, FCS and 
human serum, and different cytokines were used. 200 000 cells/ml were seeded at 
day 1. The cells were counted before media was replenished twice a week. After 24 
days the only stock that survived was the one supplemented with human serum and 
IL-6. Fourteen different conditions were examined, but only eight representative 
conditions are shown in this chart. 
 
Table 1.  Selected HH-U133-Plus-2 expression results in 47 myeloma cell lines.  
The values are normalized for 606 samples, including 559 untreated MM tumors and 
47 HMCL. The sample order is in descending order based on a MAF index (MAFI), 
with 15 HMCL and 42 of 45 MM tumors in the MF group (not shown) included among 
the 57 samples with the highest MAF index. Translocation (TLC) targets are mainly 
associated with IGH but a few involve IGL (*), IGK (§) or no detectable Ig sequences 
(#). $ All HMCL express MYC except for PE-2 and U266, which express MYCN and 
MYCL, respectively (MK, unpublished). See Materials and Methods for additional 
details. 
 
Table 2. FISH mapping of translocated chromosomes.  The positions of probes 
relative to the IGK constant region and the 5’ ends of the MYC and MAFB genes are 
indicated in kb, with negative values indicating a location 5’ of the gene.  *These 
smaller PCR (-1>+25kb) and BAC probes that were labeled with biotin and reacted 
with FITC-streptavidin uniquely detected IGK sequences at 8;20 junctions on both 
kinds of der(8). 
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Figure A. Array CGH of primary and HMCL OH-2. 
Genome-wide ratio plot of OH-2 primary cells (upper panel) and OH-2 cell line 
(bottom panel) by array CGH. 
 
Figure B. Sequencing results, primer position and sequences of the 
TP53 primers. 
There were no mutations in TP53 in the cell line. Figure B I  and B II show the 
position and sequence of the primers, respectively. OH-2 has the amino acid 
prolin in codon 72. 
 
Figure C. Sequencing of RAS in OH-2 cell line.  
OH-2 has a mutation in codon 61 in NRAS. There is no expression of HRAS, 
and KRAS2B is wild-type.  
 
Figure D.  Array comparative genomic hybridization identifies duplicated 
sequences and breakpoints in OH2 cell line. 
Copy number of OH2 genomic DNA sequences normalized to placental male 
DNA was determined by segmental analysis on Agilent custom arrays for 
chromosome 8 (A), chromosome 2 (B), and chromosome 20 (C). Affected 
translocation targets: MYC locus, 3’-enhancer of IgK, and MAFB locus are 
indicated by vertical arrows, and distances from targets to the breakpoints are 
shown above horizontal arrows.  
Abscissa: position for corresponding chromosome, bp 
Ordinate: log2 ratio of Cy5 to Cy3 signal 
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Abstract  
 
Fibroblast Growth Factor Reseptor 3 (FGFR3) is an oncogene that is dysregulated by 
the t(4;14) in multiple myeloma (MM) cells, and which is usually not expressed in MM 
cells without this translocation. By fluorescence in situ hybridization (FISH) we 
discovered an amplification of the FGFR3 locus in INA-6, an MM cell line without t(4;14). 
There was also no involvement of the other Ig loci in translocations with the FGFR3 
gene. By PCR and Western blot we demonstrated expression of FGFR3 mRNA and 
protein in the cells, probably caused by the extra copy of the gene. The FGFR3 
inhibitors SU5402 and PD173074 decreased the proliferation of INA-6, which indicates 
that FGFR3 may play a role also in cells without the t(4;14). 
 
Introduction 
     
MM is a genetically unstable malignancy of long-lived plasma cells and accounts for 
10% of all haematological malignancies. Characteristic of this neoplasm is accumulation 
of a malignant clone within the bone marrow. Multiple and complex chromosomal 
abnormalities are common in MM, and translocations involving the immunoglobulin 
heavy chain (IGH) locus on 14q32 are present in 40-60 % of patients. The five primary 
IGH translocations include 11q13, 4p16, 16q23, 6p21 and 20q12, targeting CCND1, 
FGFR3/MMSET, C-MAF, CCND3  and MAFB respectively (1). 
 
Switch translocations in MM separate the strong 3’α- and µ enhancers of IGH onto 
different derivative chromosomes. The primary t(4;14)(p16.3;q32) chromosomal 
translocation results in dysregulation of genes on both derivative chromosomes. On der4 
Multiple Myeloma SET-domain (MMSET) and on der14 fibroblast growth factor receptor 
3 (FGFR3) is the target gene involved. The translocation results in ectopic expression of 
functional (FGFR3) in 70 % of the t(4;14) patients. The IgH/MMSET fusion product is 
expressed in all t(4;14) patients (2). The MMSET isoform RE-IIBP has recently been 
shown to be a histone methyltransferase with transcriptional repression activity (3). 
MMSET has also been shown to be of importance in cellular adhesion, clonogenic 
growth and tumorigenicity (4). t(4;14) implies a poor prognosis and shorter survival after 
traditional MM treatment (5), whereas novel treatment regimens seem to be particularly 
effective in this patient group and conceal the prognostic impact of t(4;14). 
FGFR3 is one of four transmembrane tyrosine kinase receptors for the FGF family of 
ligands. Normally, FGFR3 is expressed in the kidneys and lungs and during the 
development of the nervous system and not in normal plasma cells (6). It has been 
demonstrated that FGFR3 can function as an oncogene, and contribute to tumor 
progression in MM (7, 8). It has also been shown that ectopic expression of FGFR3 
promotes cytokine independence and that inhibition of the FGFR3 promotes apoptosis 
(7, 9).  
 
It is uncommon for MM cells to express FGFR3 without a t(4;14) (10, 11). On this 
background, we here describe that the human myeloma cell line (HMCL) INA-6 has 
FGFR3 expression without the t(4;14) or any other Ig locus involvement. We also 
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demonstrate that the expression of the FGFR3 is important for survival of this particular 
cell line. 
 
Materials and Method: 
 
Cell lines 
The cell lines INA-6 (gift from Dr Gramatzki, Erlangen, Germany), OH-2 (12) and IH-1 
(13, 14) were maintained as previously reported. All three cell lines are IL-6 dependent 
(15). 
 
Fluorescence in situ Hybridization 
The probes used for fluorescence in situ hybridization (FISH) were made from Bacterial 
Artificial Chromosome clones containing the desirable regions (gift from R. Fonseca). 
For the detection of the translocations we used a fusion strategy employing two sets of 
probes, one that hybridizes to 14q32 and one that hybridizes to the desired region, 
4p16.3 or 11q13 (Table of clones in supplementary material A). The probes were 
labelled according to standard nick translation protocol (Vysis, Abbot laboratories, Des 
Plaines, IL). Centromere enumeration probe (CEP) 4 SpectrumGreen (Vysis) and Whole 
Chromosome paint (WCP) 14 in aqua (Applied Spectral Imaging (ASI), Micro System 
AB, Spånga, Sweden) were used for assessing the locus-specific probes to their 
chromosomes. Metaphase spreads were made according to standard methods (16). The 
metaphase spreads were air-dried at least over night, but not chemically treated in any 
way before hybridization. Hybridization was done after standard Vysis protocol. Cells 
were scored using a NIKON ECLIPSE 90i epifluorescense microscope with PlanApo VC 
60x/1.4 oel (Nikon Instruments Europe B.B, Badhoevedorp, The Netherlands), and 
software from Applied Imaging (CytoVision version 3.7 Build 58, San Jose, CA).  
 
Sequensing 
The four FGFR3 regions extracellular (EC) domain, transmembrane (TM) domain, 
tyrosine kinase (TK) domain and stop codon (SC) are known to be hot spots for 
activating mutations. To determine if the receptor in our cell lines was mutated, the 
receptor was amplified by reverse transcription (RT)-PCR. Total RNA was isolated using 
RNeasy Mini Kit (Qiagen, Crawley, UK) from INA-6 and IH-1 cells grown in standard 
condition. cDNA was made from RNA using SuperScript®III First Strand Synthesis 
System for RT-PCR (Invitrogen). Primer sequences were obtained from Chesi et al (7) 
(Supplementary material B). Each PCR reaction was purified with QIAquick PCR 
Purification Kit (Qiagen), and then directly sequenced using BigDye Terminator v1.1 
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA). The sequencing reaction 
was purified with DyeEx 2.0 Spin Kit (Qiagen) and analyzed on ABI3100 Genetic 
Analyzer (Applied Biosystems). 
 
Real Time RT-PCR 
RNA was isolated and cDNA made as previously described (15) from cells directly from 
stock. FGFR3 and MMSET TaqMan primers (HS00179829_m1 and HS00370212_m1 
TaqMan, Gene Expression Assays, Applied Biosystems, Foster City, CA), were used to 
detect the FGFR3 and MMSET expression. The comparative Ct-method was used for 
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quantization with GAPDH (HS99999905_m1) as housekeeping gene on the 
StepOnePlus Real-Time PCR system (Applied Biosystems).  
 
Western Blot Analysis 
Samples of IH-1, OH-2 and INA-6 were made as previously described (15). Membranes 
were blocked with non-fat dried milk (5%) in Tris-Buffered Saline supplemented with 
Tween-20 (0.05%) and incubated with antibody against FGFR3 (rabbit polyclonal IgG 
anti-FGFR3 (H-100), Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. 
GAPDH was used as loading control. Antibody binding was visualized after staining with 
horseradish peroxidise-conjugated secondary antibodies (DAKO Cytomation, 
Copenhagen, Denmark) and detection of chemiluminescense (ECL, Amersham, UK) by 
photographic film (Amersham).  
 
Cell Proliferation Assay  
Two small-molecule receptor tyrosine kinase inhibitors were employed in this study, 
each of which function in a similar manner by competing with ATP for the specific 
binding site at the catalytic domain of the fibroblast growth factor receptor. SU5402 (3-
[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone) (17) and PD173074 (1-
tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-
d]pyrimidin-7-yl]-urea) (18) were both obtained from Pfizer Global Research and 
Development. The compounds were dissolved in DMSO and stored at -80°C. Cells at a 
density of 2.0 x 104 INA-6 and IH-1, and 4.0 x 104 OH-2, were seeded in 200 µl RPMI 
supplemented with 10 % FCS with or without cytokines in 96-wells plastic culture plates 
(Corning Costar, Corning, NY, USA). Cells were starved for 4h, then SU-5402 at 
concentrations from 3,125 µM to 60 µM or PD173074 at concentrations from 6,25 nM to 
200 nM was added. After 30 min, 20 ng/ml aFGF + 100 µg/ml Heparin (compounds and 
concentrations from (18, 19)) were added. The control was only provided with 10 % FCS 
and the appropriate concentration of DMSO. Proliferation was measured as previously 
described (15). The counts per minute (cpm) obtained were normalized to the serum 
control sample and shown in figure 3.  
 
Viability test 
Flow cytometry was used to determine the percentage of viable cells with annexin V-
FITC binding and PI uptake (Apoptest-FITC kit, Nexins Research, Kattendijke, 
Netherlands). 1 x 106 cells treated as above were incubated with 0.06 µg annexin-FITC 
for 1 h and 0.5 µg PI for 5 min on ice in PBS containing 0.1 % bovine serum albumin, 
before analysis.   
 
Results and Discussion 
 
INA-6 has an abnormal pattern of 4p16 
Most reported cases of FGFR3 expression in MM are correlated to the t(4;14)POS. The 
expression is caused by the IGH enhancer or a mutated FGFR3 believed to be caused 
by somatic hypermutation (20). Here we describe a HMCL, INA-6, that has expression of 
FGFR3 without involvement of the usual t(4;14)POS. To verify the chromosomal 
abnormalities in the cell lines, metaphase FISH was used, and any IGH rearrangement 
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was detected using fusion strategy. INA-6 had an unbalanced t(11;14)POS (21) with two 
der(14) chromosomes and no der(11) (Fig. 1a). Figure 1b shows that INA-6 has triploid 
chromosome 4 with two of the chromosomes apparently normal, and one chromosome 4 
with an extra copy of locus 4p16.3, which includes both FGFR3 and MMSET on the 4p 
arm. There was no difference between the signal pattern when using the probe covering 
FGFR3 or the probe covering MMSET alone. The aberration on chromosome 4 was 
verified by array-based comparative genomic hybridization showing that the area 
spanning from 4p15.32 near the LIM domain binding 2 gene to the 4p telomere was 
amplified (data not shown). This is in concordance with the array comparative genomic 
hybridization data on INA-6 from Mayo Clinic public available at: 
http://www.broad.mit.edu/mmgp/pages/portalHome.jsf#. Because secondary 
translocations to the other Ig genes are known to dysregulate genes in MM, IGL and IGK 
were also checked with FISH on metaphase chromosomes. The light chain loci where 
shown not to be rearranged (data not shown). In figure 1c we show that IH-1 has a 
classical t(4;14)POS with FGFR3 on der(14) and MMSET on der (4) and is used as 
positive controls in the assays. OH-2 is used as a negative control because it does not 
have an IGH translocation (Våtsveen, manuscript) and does not express FGFR3. 
 
Wild type FGFR3 is expressed in both HMCLs 
To check the expression of FGFR3 in IH-1 and INA-6, Real Time RT-PCR and Western 
blots (WB) were made. Figure 2a shows Real Time data. INA-6 expressed less FGFR3 
mRNA than IH-1. OH-2 was used as a negative control that did not express FGFR3. The 
WB showed that both IH-1 and INA-6 expressed FGFR3, also here IH-1 has a higher 
expression of FGFR3 but not to the same extent as seen by the PCR. Figure 2b shows 
the WB bands of the FGFR3 in the cell lines with GAPDH used as loading control. 
Because t(4;14)POS is associated with both increased expression and activating mutation 
of the FGFR3 (22), sequencing was done, with no mutation detected in FGFR3 in either 
INA-6 or IH-1 (data not shown). 
 
Inhibition of FGFR3 leads to lower DNA synthesis and apoptosis in INA-6 and IH-1 
Inhibition of FGFR3 in MM cell lines blocks growth and is associated with apoptosis (19). 
The FGFR3 inhibitors SU5402 and PD173074 were therefore tested on INA-6, IH-1 and 
OH-2. IH-1 is used as a positive control in the experiments because of its t(4;14)POS and 
unmutated FGFR3. OH-2 is used as a negative control because it has no IGH 
translocations or FGFR3 expression (Vatsveen submitted manuscript). The proliferation 
assay measuring DNA synthesis showed decreased proliferation of unstimulated INA-6 
and IH-1 in the presence of the inhibitor SU5402 at concentrations as low as 3,25 µM 
and 15 µM, respectively (figure 3a), and with the inhibitor PD173074 at 25 nM and 50 
nM respectively (supplementary figure Ia). On the basis of the titration curve 15 µM 
SU5402 and 100 nM PD173074 was used further to show the decrease in proliferation 
with 20 ng/ml aFGF + 100 µg/ml heparin added to the cells. IH-1 was more responsive 
to the inhibitor when aFGF was added, whereas INA-6 responded in approximately the 
same way both in the presence and in the absence of aFGF (Figure 3b). PD173074 in 
concentration at 100nM gave almost identical results as with 15µM SU5402 (PD173074 
results in supplementary figure Ib). In our experiments OH-2 showed no change in 
proliferation by addition of SU5402 or PD173074, not even at concentrations 60µM 
(figure 3a) or 200nM (supplementary figure Ia) respectively, which indicates that the 
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inhibitors were not toxic at the concentrations used. We also testes effects of the 
inhibitors in a viability assay based on annexin V binding. Figure 3c shows the viability of 
aFGF-stimulated cells with and without SU5402 inhibitor. In INA-6, the percentage of 
viable cells with the inhibitor was almost zero. IH-1 had also a decline in the percentage 
viable cells, but not to the same degree as INA-6, paralleling the relative responses of 
the two cell lines in the proliferation assay (viability data for PD173074 in supplementary 
figure Ic). OH-2 had no significant change in the viability with inhibitor added. It has 
earlier been demonstrated that even at 72-hour stimulation, PD173074 is not cytotoxic to 
myeloma cells (23). We thereby assume that the decreased proliferation and apoptosis 
seen in IH-1 and INA-6 was due to specific inhibition of the FGFR3. For INA-6 the extra 
copy of FGFR3 and the abnormal position of the locus can possibly explain the FGFR3 
detected on WB and the ability the inhibitors have to lower proliferation and enhance 
apoptosis. It also shows that the expression of FGFR3 is important for the survival in 
these cell lines. 
 
Because expression of FGFR3 in t(4;14) NEG only has been reported in a few cases (10, 
11, 24), it is likely that FGFR3 expression is not very common in t(4;14)NEG patients. 
Even though FGFR3 expression is rare in t(4;14) NEG, INA-6 can be a good model to 
elucidate the role of FGFR3 in MM cells. Since it does not express MMSET at a high 
level, contrary to all the t(4;14)POS cell lines (supplementary data II), and, hence, lacks 
the IGH/MMSET fusion transcript, it might be useful as a model system for investigating 
FGFR3’s role in MM cells independently of the interaction of high levels of MMSET.  
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Figure legends  
 
Figure 1. Fluorescence in vitro hybridization on metaphase spreads is used to 
identify chromosomal abnormalities in the HMCLs.  
a) INA-6 has an unbalanced t(11;14) with two copies of der(14). IGH is labelled in green 
and 11q13 CCND1 in red. Four copies of chromosome 11 is found in the HMCL; b) 
Probes for FGFR3 and MMSET red shows a extra copy of the 4p16.3 loci on one of the 
chromosome 4 p-arm. CEP4 green confirms that the genes are present on chromosome 
4; c) IH-1 has a classical t(4;14). IGH is labelled in green FGFR3/MMSET in red. 
 
Figure 2.  Real Time RT-PCR and Western Blot confirm FGFR3 expression in INA-6 
a) Real Time RT-PCR shows FGFR3 expression in both INA-6 and IH-1 with a higher 
expression in IH-1. Delta Ct-method with GAPDH as control is used for the relative 
quantisation. Western Blot shows IH-1 and INA-6 expresses FGFR3, with OH-2 as a 
negative control with no FGFR3 expression.  
  
Figure 3.  SU5402 and PD173074 similarly decrease proliferation measured as 
DNA synthesis and viability in HMCLs expressing FGFR3 
a) HMCL OH-2, INA-6 and IH-1 were treated with the FGFR3 inhibitor SU5402 in 
increasing concentrations from 3,25µM to 60µM and plotted against relative proliferation 
where 1 was set as proliferation in untreated (10% FCS and DMSO only) cells. 
Proliferation is measured as DNA synthesis by 3H-Tymidin incorporation. The 
proliferation decreased significantly in both INA-6 and IH-1 in as low concentrations as 
15µM, whereas OH-2 was unaffected by the inhibitors even at 60µM where both IH-1 an 
INA-6 had a very low proliferation. Error bars represent standard deviation of triplicates. 
b) The HMCLs where also grown with either 20ng/ml aFGF+100µg/ml heparin or in the 
presence of only serum and DMSO. Each condition was treated with or without the 
FGFR3 inhibitor SU5402 at 15µM. In both INA-6 and IH-1 aFGF + heparin induced cell 
proliferation, and, SU5402 led to a decrease in DNA-synthesis in both unstimulated and 
aFGF + heparin stimulated cells. In IH-1 the decrease in proliferation is greater when 
treated with aFGF compared to untreated control. OH-2 do not express FGFR3, and 
inhibition of the FGFR3 has no effect in this cell line. Error bars represent standard 
deviation of triplicated data. (Counts per minute were normalized to 1 to the HMCLs 
sample with serum, for simplification) 
c) OH-2, INA-6 and IH-1 with the same conditions as in b) were labelled with PI and 
annexin to measure the viable cells with flow cytometry. 15µM SU5402 with 20ng/ml 
aFGF+100µg/ml heparin is shown as an example. The inhibitors drastically decreased 
the viability in INA-6. In IH-1 the overall viability are a bit higher than in INA-6, but is also 
decreased with the inhibitors. OH-2 has as expected no significantly difference in 
viability with or without the inhibitors. The low % of viable cells in untreated sample OH-2 
and INA-6 is what we always experience when the cells are grown for more than over 
night without IL-6. Error bars represent standard deviation of duplicated flow data. All 
data shown in figure 3 are representative for at least two separate experiments. The 
results with FGFR3 inhibitor PD173074 is shown in supplementary figure I.  
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Supplementary figure legends 
 
Supplementary Table A: 
FISH probes are made from isolated Bacterial Artificial Clones covering the desired 
regions listed below. 
 
Supplementary Table B: 
Primers for sequencing the FGFR3 receptor are listed below. 
 
Supplementary figures: 
Figure Ia: HMCL OH-2, INA-6 and IH-1 were treated with the FGFR3 inhibitor 
PD173074 in increasing concentrations from 6,25 nM to 200nM and plotted against 
relative proliferation where 1 was set as proliferation in untreated (10% FCS and DMSO 
only) cells. Proliferation is measured as DNA synthesis by 3H-Tymidin incorporation. The 
proliferation decreased significantly in both INA-6 and IH-1 in as low concentrations as 
25nM and 50nM respectively, whereas OH-2 was unaffected by the inhibitors even at 
200nM where both IH-1 an INA-6 had low proliferation. Hence the concentration used in 
later experiments is not toxic to the cells. Error bars represent standard deviation of 
triplicates. 
Figure Ib: 
The HMCLs where also grown with either 20ng/ml aFGF+100µg/ml heparin or only 
serum and DMSO. Each condition was treated with or without the FGFR3 inhibitor 
PD173074 at 100nM. In both INA-6 and IH-1 aFGF + heparin induced cell proliferation, 
and the inhibitor it led to a decrease in DNA-synthesis in unstimulated and aFGF+ 
heparin stimulated cells. In IH-1 the decrease in proliferation is greater when treated with 
aFGF compared to untreated control. OH-2 do not express FGFR3, and inhibition of the 
FGFR3 had no effect in this cell line. Error bars represent standard deviation of 
triplicated data. (Counts per minute were normalized to 1 to the HMCLs sample with 
serum, for simplification) 
Figure Ic: 
OH-2, INA-6 and IH-1 with the same conditions as in figure II were labelled with PI and 
annexin to measure the viable cells with flow cytometry. The PD173074 drastically 
decreased the viability in INA-6 and IH-1. OH-2 has as expected no significantly 
difference in viability with or without the inhibitors. Error bars represent standard 
deviation of duplicated flow data. All data shown in figure 3 are representative for at 
least two separate experiments. 
 
Figure II 
Relative Quantitative Real Time PCR. TaqMan probes for MMSET (Hs00370212_m1, 
TaqMan) was used or detecting relative MMSET expression in OH-2, INA-6 and IH-1 
cells directly from stock. The comparative Ct-method was used for quantization with 
GAPDH (HS99999905_m1, TaqMan) as housekeeping gene. INA-6 had approximately 
double expression of MMSET compared to OH-2 which could be explained with the fact 
that INA-6 has four copies of the gene whereas OH-2 has two copies. IH-1 which has a 
IGH/MMSET fusion transcript (not shown) has more than four times as much MMSET as 
INA-6, and is regulated by the IGH enhancers. 
Supplementary data
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Figure II
Supplementary Table A: Probes for FISH 
Gene Locus Probe name/BAC-clone 
IgH 14q32.33 CH 
  Ig6 
  U2-2 
  364 
  VH 
IgKc 
IgK v 
2p11.2 
RP11-15J7 
RP11-433C18  
IgLc 22q11.22 CTD-2194H2  
IgLv  RP11-22M5 
RB-1 13q14 RP11-305D15 
 
 
 
 
RP11-174I10 
 
TP53 17p13 RP11-89D17 
Myeov 11q13 1144 
  505 
Cyclin D1  365 
  J 
  C 
  E 
  B 
 
MMSET 4p16.3 184D6 
FGFR3 4p16.3 293022 
 
Supplementary Table B: Primer sequences for FGFR3 
FGFR3 region Base pair Primer  Sequence 5’-3’direction 
EC 117 F:o5666 
R:o5706
CGG CAG ACG TAC ACG CTG  
CTT GCA GTG GAA CTC CAC GTC 
TM 442 
 
F:o5580 
R:o202 
GCG CTA ACA CCA CCG ACA AG 
CTC CCC TGA GGA CAG CCT TGC GAT 
TK 120 F:o5724 
R:o5703
ATG AAG ATC GCA GAC TTC GGG 
GTA GAC TCG GTC AAA CAA GGC 
SC 313 F:o66 
R:o5725
CTC CCA GAG GCC AAC CTT CAA GCA G 
ATC TGC ACT GAG TCT CAT GCC 
F: forward primer, R: reverse primer 
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Abstract 
 
Multiple myeloma (MM) is a genetically unstable malignancy of long-lived 
plasma cells (PC), and complex chromosomal abnormalities such as 
translocations involving the immunoglobulin heavy chain (IGH) are common. 
The easiest way to detect genetic aberrations in MM patients is by interphase 
fluorescence in situ hybridization (FISH).  
In this study we wanted to use interphase FISH to find the prevalence of the 
most common primary translocations and deletions in chromosome 13 and 17 
in Norwegian MM patients. This study includes 139 bone marrow samples 
from newly diagnosed MM patients. The incidence was: 57 (41%) patients 
had an IGH translocation, 42 (30%) patients had del13 out of which 20 had 
del13 as only known aberration, 24 (17%) patients had del17 and 54 (38%) 
patients had none of the aberrations we looked for. Of the IGH translocations 
23 (16%) patients had t(11;14), 17 (12%) patients had t(4;14), 2 (1.5%) 
patients had t(6;14) and 1 (1%) patients had t(14;16). 14 (10%) patients had 
an unknown IGH translocation. Clinical information was collected in a subset 
of 65 patients. There was no significant correlation between clinical findings 
and genetics in these 65 patients.  
 
Introduction 
 
Multiple myeloma (MM) is a genetically unstable malignancy of long-lived 
plasma cells (PC) in the bone marrow (BM) and accounts for 10% of all 
haematological malignancies. Multiple and complex chromosomal 
abnormalities are common in MM, and translocations often involve the 
immunoglobulin heavy chain (IGH). Primary translocations involving an IGH 
locus are reported to be present in nearly 50% of pre-malignant monoclonal 
gammopathy of undetermined significance (MGUS), approximately 60% of 
fully malignant MM tumors, and nearly 90% of human multiple myeloma cell 
lines. In primary translocations one or all of the strong IGH enhancers are 
juxtaposed to an oncogene/proto-oncogene. The switch translocations in MM 
cells separate the strong 3`α- and µ-enhancers of the IGH onto different 
derivative chromosomes. The enhancers can thereby turn on the transcription 
of the juxtaposed genes. The reciprocal partners to IGH are: 4p16, 
MMSET/FGFR3; 11q13, Cyclin D1; 12p13, Cyclin D2; 6p21, Cyclin D3; 
16q23, MAF; 20q12, MAFB and 8q24.3, MAFA1-4.  
 
The t(4;14)(p16.3;q32) and t(11;14)(q13;q32) are the most common 
translocations and are present in 15% of newly diagnosed patients. The t(4;14 
has not been described in other malignancies5. This translocation was also 
the first example to show that IGH could dysregulate two genes at two 
derivative chromosomes, namely fibroblast growth factor receptor 3 (FGFR3) 
and multiple myeloma SET domain (MMSET)6. The translocation results in 
ectopic expression of functional FGFR3 in 70 % of the t(4;14) patients, but is 
associated with poor prognosis irrespective of FGFR3 expression7,8. However, 
the chimeric IGH/MMSET gene fusion product is expressed in all t(4;14) 
patients8,9. t(4;14) patients with low β2-microglobulin (B2M) level have shown 
longer survival compared to those with high levels. Genetic studies also imply 
that ~80-85% of t(4;14) patients have a deletion (del)13. These two 
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abnormalities together show a worse prognosis than t(4;14) alone10. It has, 
however, been reported that it is the t(4;14) and not the del13 that is the 
important adverse prognosis factor at least in relation to autologous stem cell 
transplantation11. The t(11;14)(q13;q32) involves cyclin D1 at 11q13 encoding 
the cyclin D1 protein is over-expressed as a consequence of this 
translocation12. Early studies reported the t(11;14) patients to have longer 
survival13. Later and larger studies did not confirm this better survival10,14. The 
t(6;14)(p21;q32) dysregulates cyclin D3 and is present in ~5% of myeloma. 
The t(14;16)(q32;q23) dysregulates MAF and is present in ~5% of MM 
patients15. This translocation is also unique for MM patients and has an 
unfavourable prognosis5. The t(14;20)(q32;q11) dysregulates MAFB, and is 
present in less than 1% of MM patients16.  
 
Del13 was one of the first genetic markers to be demonstrated to predict a 
negative outcome17-19, and is found in about half of MM karyotypes20. In the 
recent Intergroup Francophone du Myelome (IFM) study, del13 identified with 
interphase fluorescence in situ hybridization (FISH) was not an independent 
prognostic factor, but was associated with poor prognosis related to the 
concomitant t(4;14) or del17p. Del13 may be considered a pseudomarker or a 
marker frequently associated with other more specific poor prognostic factors 
10. In MM it has more recently been found a deletion in chromosome 17p in 
10% of newly diagnosed patients. TP53 is located on 17p13 and down-
regulation of the gene expression was correlated to the 17p13 deletion, which 
therefore makes TP53 likely to be the most important gene in the deleted 
locus. Del17 is associated with poor outcome10.  
 
Secondary translocations occur during late stage of MM progression and do 
not involve B-cell-specific DNA modification mechanisms. Secondary 
translocations also include the IGL gene (10%) and IGK (<1%)21. The 
secondary translocations are rarely reciprocal, and can also be complicated 
insertions of the genes. Almost 20% of MM patients with IGH translocation 
involved a non-recurrent translocation partner5,22. 
 
According to previous studies using interphase fluorescence in situ 
hybridization (FISH), translocations and deletions have been associated with 
unique biological, clinical, and prognostic features4,5. We aimed to investigate 
the prevalence of the following genetic aberrations at the time of diagnosis in 
Norwegian MM patients; IGH translocations, t(4;14), t(11;14), t(6;14), t(14;16), 
del13 and del17. Furthermore, we wanted to investigate a possible correlation 
between these genetic aberrations and clinical stage, β2-microglobulin (B2M), 
type of immunoglobulin and bone disease in patients at time point of 
diagnosis. A further motivation for the study is the emerging differentiated 
treatment according to cytogenetic aberration. 
 
Material and methods 
 
Patient samples 
From January 2006 to December 2008, 161 BM aspirates were investigated 
by interphase FISH. The patient material represents approximately 1/5 of the 
patients diagnosed with MM in Norway during the same period. After 
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exclusions as shown in figure 1, we report results from 139 newly diagnosed 
patients. The female to male ratio in the MM patient group was 1:1.8 and the 
median age at sampling was 68 (range 29-90 years) years. 80% of the 
samples were shipped with over night post from hospitals outside Trondheim. 
Clinical information about the myeloma patients was obtained from the 
patients records. Clinical information was available for 65 patients. Registered 
information was: stage according to Durie Salmon (DS) and International 
Scoring System (ISS), type and concentrations of serum and urine M-protein, 
PC percentage in bone marrow aspirate, serum β2-Microglobulin and bone 
lesions. Bone lesions were scored semi-quantitatively from x-ray findings, and 
assigned into three groups: 0 = no bone lesions, 1 = ≤ 5 bone lesions, and 2 = 
more than 5 bone lesions. The median age of these 65 MM patients at 
sampling was 65 (range 37-90 years) years and female to male ratio 1:1.8. 
The distribution of serum Ig-class was IgG type in 24 patients (40%), IgA in 17 
patients (26%), other Ig isotypes in 1 (2%) patients, only light chain secretion 
in 14 (22%) patients, and non-secretary myeloma in 1 (2%) patients. For 8 
(12%) patients no information was available. 20 (31%) patients were in stage 
1 according to the ISS, 17 (26%) patients in stage 2 and 14 (22%) in stage 3.  
For 13 (20%) patients no information was available.   
   
2-3 ml of bone marrow was aspirated from the crista iliaca into a EDTA-tube 
(Vacuette, Greiner Bio-One GmbH, Austria). The bone marrow aspirate of in-
house samples and shipped samples were received at the Laboratory of 
Hematology St. Olav’s University Hospital. Mononuclear cells (MNC) were 
enriched using Cell Preparation Tubes with citrate (CPT tubes, BD 
Vacutainer, Franklin Lakes, USA). Three methods for PC evaluation were 
used, BM smears, cytospins of MNCs or CD138 separated cells. Before 
March 2008, FISH was performed with cytoplasmatic-immunoglobulin-(cIg)-
FISH on cytospins from MNC or on BM smears. cIg-FISH uses a AMCA- (7-
amino-4-methylcoumarin-3-acetic acid) conjugated goat anti-human Igλ and 
Igκ (Vector laboratories, Brulingame, CA) which bind the light chains in the 
cytoplasm of the PC allowing specific detection of the PC in the samples. 
After March 2008 the PC were separated from MNC by immunomagnetic cell 
selection with CD138 monoclonal antibodies using the RoboSep (StemCell 
Technologies, Vancouver, BC, Canada) cell separation device. Cytospin with 
~10-30 000 of the CD138 positive selected MM and with 50 000 of MNC were 
used. One slide was always stained with May Grünwald-Giemsa to verify the 
PC % and the purity of the cells. With CD138 separation, cells from freshly 
drawn samples with more than 10 mill MNC were usually >98% pure and 
samples sent to us by over night post >95% pure. Samples shipped over night 
with fewer than 10 mill MNC might be down to 90% pure, but this is still good 
enough to use for FISH analysis. All samples were fixed in 100% EtOH for 5 
min, room temperature, before storing in -20°C until FISH was performed.  
 
FISH probes 
The probes used for the primary IGH translocations were made from Bacterial 
Artificial Chromosome (BAC) clones containing the desirable region (gift from 
R. Fonseca). BACs for probes covering CCND3, MYC, TP53 and RB1 were 
purchased from BACPAC resources (BACPAC resources, Children’s Hospital 
Oakland, CA). All clones are listed in supplementary table A. The probes were 
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labeled with SpectrumGreen or SpectrumOrange dUTPs (Vysis, Abbot 
Laboratories, Des Plaines, IL) according to standard nick translation protocol 
(Vysis). Before the start of the study the probes were hybridized to normal 
cells for control. All probes had an hybridization efficiency higher than 95%. 
For some samples commercial IGH brake apart probe, t(4;14), t(11;14), LSI 
RB-1 and LSI TP53 were used (Vysis). The strategy for identifying the IGH 
translocations is by IGHc/IGHv break apart probe before looking for the 
specific IGH translocation using dual fusion strategy. 
 
FISH procedure 
The cells were fixed in methanol/acetic acid (1:3 vol/vol) (-20°C, 40 min) and 
air dried. Probe mix (100 ng labelled DNA probe in 3 µl H2O + 7µl LSI 
hybridization Buffer (Vysis)). 2,5 µl probe mix was used for cytospin samples 
and 10 µl for BM smears. The probe mix was sealed with cover glass and 
rubber sement. Hybridization was done in a Dako hybridizer (Dako 
Cytomation, Glostrup, Denmark). Program: Denaturation (10 min, 75°C) 
Hybridization (10-18 h, 37°C). Posthybridization wash was performed in 0.4 x 
SSC/0.3% NP-40 (pH 7.0-7.5, 72°C, 2 min), then 2xSSC/0.1% NP-40 (pH 7.0-
7.5, RT, 6-60 s). For cIgFISH, the slides were directly put in 1x phosphate 
buffer saline (PBS) for 5 min then incubated with goat serum (15% in 1xPBS) 
(Invitrogen, Carlsbad, CA) for 5 min. The serum was poured off and incubated 
with AMCA conjugated goat-IgG anti-human Igλ/Igκ (1:200 in 3% BSA in 1x 
PBS) (Vector laboratories) for 10 min. The signal was amplified with a second 
AMCA labeled anti-goat IgG antibody (Vector laboratories). Slides were 
washed for 2x 10 min in 1x PBS, then air-dried and anti-fade added 
(Vectashield hard-set mounting medium without DAPI, (Vector Laboratories). 
All steps in the immunostaining were done at RT. For CD138 separated cells 
slides were air dried after the posthybridization wash and anti-fade with DAPI 
applied (Vectashield hard-set mounting medium with DAPI, (Vector 
Laboratories)). FISH was scored using NIKON ECLIPSE 90i epifluorescence 
microscope with PlanApo VC 100x/1.4oel (Nikon Instruments Europe B.V, 
Badhoevedorp, The Netherlands), and software from Applied Imaging 
(CytoVision, version 3.7 Build 58, 2005, San Jose, CA). 
 
Scoring of FISH  
All slides were scored by the same person. For every probe set 100 
interphase nuclei were scored. Cut-off levels were used according to the 
European Myeloma Network23: deletions ≥ 20% of evaluated cells; split 
signals and translocations ≥10% of evaluated cells. Slides with <95% 
hybridization efficacy in non-PC cells were not used. For cIgFISH all 
evaluated cells must have positive immunostaining and the typical 
morphology of the PC seen by May Grünwald-Giemsa staining. The 
percentage PC in the samples were determined by May Grünwald-Giemsa 
staining. For samples where less than 25 nuclei were possible to score, the 
specimens were considered non-informative. If only 25-50 cells were possible 
to score more than 50% of the cells must have a given aberration, to be 
considered positive for the genetic aberration. If more than 90% of the 25-50 
cells had normal signal pattern the samples were considered normal, if less 
than 50% of the cells had a given abnormality or less than 90% were normal 
the specimen were considered non-informative. For cells with informative 
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interphase nuclei between 50 and 100 cells normal cut-off levels were used. 
For non-informative samples a new sample, if available, was used to redo the 
experiment, and if e.g. cytospin of MNC gave non-informative result a BM 
smear could be used. After the introduction of CD138 selection of cells, the 
procedure was considerably improved, and all samples gave informative 
result.  
 
Statistics 
SPSS Statistical Software version 14.0 was used for statistic calculations 
(SPSS Inc., Chicago, IL). Pearsons’ χ2 or Fisher’s exact tests were used for 
between-group comparison of discrete variables, and Mann Whitney U test 
was used for continuous variables. The level of statistical significance was set 
at p < 0.05. P-values were 2-tailed. 
 
Ethics 
The work presented is a part of the Norwegian national biobank for multiple 
myeloma (4.2005.1438), and this particular study was approved by the 
Regional Ethic Committee (4.2007.933). All patients sign an informed consent 
form according to the Declaration of Helsinki. 
 
Results 
 
Genetic aberrations and clinical disease parameters 
Of the 147 samples from patients with reported MM, 139 were analyzed after 
excluding MGUS, non-MM samples and not newly diagnosed patients. The 
most common aberration found was as expected IGH translocations and 
del13. 57 (41%) patients had an IGH translocation, 42 (30%) patients had 
del13 out of which 20 had del13 as the only detected aberration, 24 (17%) 
patients had del17 and 54 (38%) patients had none of the aberrations we 
looked for. Of the IGH translocations 23 (16%) patients had t(11;14), 17 (12%) 
patients had t(4;14), 2 (1%) patients had t(6;14) and 1 (1%) patients had 
t(14;16). 16 (11%) patients had an IGH translocation with an unknown 
partner. Half of the patient samples with unknown translocation testing was 
only done for t(4;14) and t(11;14), because of lack of material. The prevalence 
of the abnormalities was the same in all age categories of the patients. There 
was significant correlation between del13 and del17. Del13 was seen in 12 
(50%) of the 24 patients with del17, and in 30 (26%) of the 115 patients 
without del17, odds ratio 2.83, 95% confidence interval (1.15, 6.98), p = 0.02. 
There was no significant correlation between del13 or del17 and the IGH 
translocations. Only 41 % of the t(4;14) patients had del13 simultaneously. 
The various combinations of aberrations are summarized in a Venn diagram 
in figure 2.   
 
For 48 patients, B2M levels were known. There was no significant correlation 
between B2M levels and the IGH translocations del13 or del17. However, 
when patients with any of these genetic aberrations were analyzed together 
as a group, the B2M levels were significantly higher than in patients with no 
detected aberration, with median B2M 4.3 mg/L (range 1.6-50.9) and 2.8 mg/L 
(range 1.0-11.2), respectively, p = 0.02. 
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There was no significant correlation between genetic aberrations and bone 
disease, ISS or DS stage, type of immunoglobulin or light chain at diagnosis.  
  
 
Discussion 
 
MM cells are characterized by genetic instability and chromosomal 
abnormalities24. In this FISH study we found that IGH translocations were the 
most frequent chromosomal abnormality. We found it at lower frequency than 
in many other studies, which reports ~60% in MM25,26, however, two studies 
from the UK find IGH translocations in 44-45% of their patients27,28. Table 1 
gives an overview of genetic aberrations reported from different countries. 
The studies indicate that the prevalence of IGH translocations in MM is lower 
in the Northwestern part of Europe although a random variation of the studies 
cannot be ruled out. The specific translocations t(11;14) and t(4;14) are 
present in approximately the same frequency as in other studies29. Is might be 
reasonable to speculate if the “correct” number primary translocations, and 
lower overall IGH translocations are due to the fact that all patients are newly 
diagnosed in the present study? If the patients included are diagnosed at an 
earlier stage of the disease than in other countries, the secondary IGH 
translocation might not yet have arisen or they are present below the cut-off 
level. Others have shown that aberrations increase during the progression of 
the disease30. For the t(14;16) and t(6;14) the results are lower than others 
have published29. The explanation for this is most likely that for eight of the 16 
t(?;14) patients there was not enough material left or the quality of the 
material left was poor. Hence, the test for t(6;14) and t(14;16) was not done 
on these patient samples. The del13 was present in the same frequency as in 
a Danish study30, but at lower level than in other studies19. For del17 the 
frequency was almost as others have found31.  
 
There was a significant correlation between del13 and del17. This is an 
interesting and novel finding. There was, however, no significant correlation 
between neither del13 nor del17 and the primary IGH translocations, which 
was quite surprising, given that others have published that 80-85% of t(4;14) 
patients have a del1320,32. Also there was no correlation between del13 and 
IGH translocations as a group, whereas others have found that they are 
correlated20,33.  
 
The level of B2M has in many studies been demonstrated to correlate with 
prognosis34, and it is also a factor in the ISS staging. There was no significant 
difference in B2M between the specific genetic groups. However, we found a 
higher level of B2M in the patients with genetic aberrations analyzed as a 
group.  
 
There was no significant correlation between genetic aberrations and bone 
disease, stage according to ISS or DS, type of immunoglobulin or light chain 
at diagnosis. A correlation between genetic aberrations and stage and 
prognosis has been shown by others31. They did, however, not use samples 
from newly diagnosed patients which could explain the difference between our 
findings. There was also no significant correlation with the genetic aberrations 
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and type of immunoglobulin or type of light chain, even though a correlation 
has been shown by others13. 
 
The detection of genetic abnormalities can be important to predict prognosis 
in patients and to predict responses to treatment. Recently bortezomib was 
shown to be beneficial for t(4;14) patients35 and it also seemed to overcome 
some of the poor prognosis in del13 patients36,37. In the University of 
Arkansas for Medical Science total therapy study II patients with non 
favourable cytogenetics/gene expression profile (GEP) group benefited the 
most from thalidomide, and they had a significantly better overall and event 
free survival compared to the same non-favourable cytogenetics/GEP control 
group. Conversely, it was noted that patients without cytogenetic 
aberrations/favourable GEP did not have the same benefit from thalidomide 
treatment38.  
 
The establishment of the method and estimate of the prevalence of genetic 
aberrations in MM patients in Norway may have significant implications for 
future treatment strategy 
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Figure 1. Flow chart of the included patients samples of the study 
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Figure 2. Venn diagram of the most common aberrations found in the 
study of MM patients in Norway. 
The most common aberration is the IGH translocation (57 of 139 patients). 54 
patients with IGH translocation are shown, 2 patients with t(6;14) and 1 
patient with t(14;16) are not drawn in the diagram. 42 patients had a del13, in 
which 20 the del13 was the only known aberration. For del17 2/3 of the 
patients had the del17 together with another known aberration. 23 patients 
had a t(11;14), in which 2/3 had no other known aberration.  For t(4;14) only 
half of the patients had no other known aberration. The only aberrations that 
are significantly correlated are del13 and del17. 
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Supplementary Table A: Probes for FISH 
Gene Locus 
Probe 
name/BAC-
clone 
IgH 14q32.33 CH 
  Ig6 
  U2-2 
  364 
  VH 
IgKc 
IgK v 2p11.2 
RP11-15J7 
RP11-433C18  
IgLc 22q11.22 CTD-2194H2  
IgLv  RP11-22M5 
RB-1 13q14 RP11-305D15 
 
 
 
 
RP11-174I10 
 
TP53 17p13 RP11-89D17 
Myeov 11q13 1144 
  505 
Cyclin D1  365 
  J 
  C 
  E 
  B 
 
MMSET 4p16.3 184D6 
FGFR3 4p16.3 293022 
MAF 
 
16q23 
 
10205 
10206 
 
Cyclin D3 
 
6p21 
 
RP11-720D9 
RP11-298J23 
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